|
G |
Akr1b1 |
aldo-keto reductase family 1 member B |
increases oxidation |
ISO |
AKR1B1 protein results in increased oxidation of Benzyl Alcohol |
CTD |
PMID:17194029 |
|
NCBI chr 4:61,706,866...61,720,959
Ensembl chr 4:61,706,864...61,720,956
|
|
G |
Akr1b8 |
aldo-keto reductase family 1, member B8 |
multiple interactions |
EXP |
[AKR1B8 protein co-treated with NADP] affects the oxidation of Benzyl Alcohol |
CTD |
PMID:18845131 |
|
NCBI chr 4:61,772,064...61,784,637
Ensembl chr 4:61,771,970...61,828,657
|
|
G |
Il1a |
interleukin 1 alpha |
increases expression |
ISO |
Benzyl Alcohol results in increased expression of IL1A protein |
CTD |
PMID:19878710 |
|
NCBI chr 3:121,824,712...121,836,122
Ensembl chr 3:121,825,412...121,836,086
|
|
G |
Lif |
LIF, interleukin 6 family cytokine |
increases expression |
ISO |
Benzyl Alcohol results in increased expression of LIF protein |
CTD |
PMID:19878710 |
|
NCBI chr14:84,482,652...84,500,574
Ensembl chr14:84,482,674...84,500,642
|
|
G |
Sult1a1 |
sulfotransferase family 1A member 1 |
increases sulfation |
ISO |
SULT1A1 protein results in increased sulfation of Benzyl Alcohol |
CTD |
PMID:26663444 |
|
NCBI chr 1:198,100,586...198,104,106
Ensembl chr 1:198,100,586...198,104,109
|
|
G |
Sult1b1 |
sulfotransferase family 1B member 1 |
increases sulfation |
ISO |
SULT1B1 protein results in increased sulfation of Benzyl Alcohol |
CTD |
PMID:26663444 |
|
NCBI chr14:22,142,412...22,155,246
Ensembl chr14:22,142,364...22,155,231
|
|
G |
Ugt2b17 |
UDP glucuronosyltransferase family 2 member B17 |
increases glucuronidation |
EXP |
UGT2B1 protein results in increased glucuronidation of Benzyl Alcohol |
CTD |
PMID:8302279 |
|
NCBI chr14:22,724,399...22,736,148
Ensembl chr14:22,724,070...22,825,444
|
|
|
G |
Enpp2 |
ectonucleotide pyrophosphatase/phosphodiesterase 2 |
increases expression |
ISO |
benzyl acetate results in increased expression of ENPP2 mRNA; benzyl acetate results in increased expression of ENPP2 protein |
CTD |
PMID:22952646 |
|
NCBI chr 7:94,479,931...94,563,086
Ensembl chr 7:94,480,396...94,563,001
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
increases expression |
ISO |
benzyl acetate results in increased expression of MMP9 mRNA; benzyl acetate results in increased expression of MMP9 protein |
CTD |
PMID:22952646 |
|
NCBI chr 3:161,413,410...161,421,473
Ensembl chr 3:161,413,298...161,421,520
|
|
G |
Ppp3ca |
protein phosphatase 3 catalytic subunit alpha |
multiple interactions |
ISO |
benzyl acetate results in increased cleavage of and results in increased activity of PPP3CA protein |
CTD |
PMID:22952646 |
|
NCBI chr 2:241,909,332...242,186,861
Ensembl chr 2:241,909,832...242,184,854
|
|
|
G |
Atf3 |
activating transcription factor 3 |
increases expression |
ISO |
benzyl benzoate results in increased expression of ATF3 mRNA |
CTD |
PMID:27965148 |
|
NCBI chr13:109,817,892...109,849,632
Ensembl chr13:109,817,728...109,849,632
|
|
G |
Cd86 |
CD86 molecule |
increases expression |
ISO |
benzyl benzoate results in increased expression of CD86 protein |
CTD |
PMID:29540657 |
|
NCBI chr11:67,060,305...67,117,990
Ensembl chr11:67,082,193...67,118,795
|
|
G |
Esr1 |
estrogen receptor 1 |
multiple interactions |
ISO |
benzyl benzoate inhibits the reaction [Estradiol binds to ESR1 protein] |
CTD |
PMID:19338011 |
|
NCBI chr 1:41,192,029...41,594,799
Ensembl chr 1:41,192,824...41,594,796
|
|
G |
Esr2 |
estrogen receptor 2 |
multiple interactions |
ISO |
benzyl benzoate inhibits the reaction [Estradiol binds to ESR2 protein] |
CTD |
PMID:19338011 |
|
NCBI chr 6:99,163,953...99,214,711
Ensembl chr 6:99,164,357...99,214,251
|
|
G |
Maoa |
monoamine oxidase A |
decreases activity |
ISO |
benzyl benzoate results in decreased activity of MAOA protein |
CTD |
PMID:27270453 |
|
NCBI chr X:6,554,698...6,620,722
Ensembl chr X:6,554,698...6,620,722
|
|
G |
Maob |
monoamine oxidase B |
decreases activity |
ISO |
benzyl benzoate results in decreased activity of MAOB protein |
CTD |
PMID:27270453 |
|
NCBI chr X:6,430,694...6,533,520
Ensembl chr X:6,430,594...6,533,534
|
|
G |
Nefh |
neurofilament heavy |
affects expression |
EXP |
benzyl benzoate affects the expression of NEFH mRNA |
CTD |
PMID:22954530 |
|
NCBI chr14:85,181,572...85,191,557
Ensembl chr14:85,181,572...85,191,557
|
|
G |
Tff1 |
trefoil factor 1 |
increases expression |
ISO |
benzyl benzoate results in increased expression of TFF1 mRNA |
CTD |
PMID:19338011 |
|
NCBI chr20:9,892,124...9,895,984
Ensembl chr20:9,892,124...9,895,984
|
|
|
G |
Adipoq |
adiponectin, C1Q and collagen domain containing |
increases expression |
ISO |
benzylparaben results in increased expression of ADIPOQ mRNA |
CTD |
PMID:22956630 |
|
NCBI chr11:81,330,845...81,344,488
Ensembl chr11:81,330,293...81,344,488
|
|
G |
Afp |
alpha-fetoprotein |
affects binding |
EXP |
benzylparaben binds to AFP protein |
CTD |
PMID:23013281 PMID:25349334 |
|
NCBI chr14:19,141,755...19,159,919
Ensembl chr14:19,141,755...19,159,923
|
|
G |
Cebpa |
CCAAT/enhancer binding protein alpha |
increases expression |
ISO |
benzylparaben results in increased expression of CEBPA mRNA |
CTD |
PMID:22956630 PMID:27659731 |
|
NCBI chr 1:91,363,492...91,366,164
Ensembl chr 1:91,363,492...91,366,164
|
|
G |
Esr1 |
estrogen receptor 1 |
multiple interactions |
ISO |
benzylparaben binds to and results in increased activity of ESR1 protein |
CTD |
PMID:23220609 PMID:23567241 |
|
NCBI chr 1:41,192,029...41,594,799
Ensembl chr 1:41,192,824...41,594,796
|
|
G |
Esr2 |
estrogen receptor 2 |
multiple interactions |
ISO |
benzylparaben binds to and results in increased activity of ESR2 protein |
CTD |
PMID:23567241 |
|
NCBI chr 6:99,163,953...99,214,711
Ensembl chr 6:99,164,357...99,214,251
|
|
G |
Esrrg |
estrogen-related receptor gamma |
multiple interactions |
ISO |
benzylparaben inhibits the reaction [afimoxifene inhibits the reaction [ESRRG protein binds to NCOA2 protein]] |
CTD |
PMID:23583298 |
|
NCBI chr13:106,063,799...106,683,353
Ensembl chr13:106,463,368...106,683,436
|
|
G |
Faah |
fatty acid amide hydrolase |
decreases activity |
ISO EXP |
benzylparaben results in decreased activity of FAAH protein |
CTD |
PMID:27659731 |
|
NCBI chr 5:134,852,899...134,872,095
Ensembl chr 5:134,852,875...134,871,775
|
|
G |
Faahl |
fatty-acid amide hydrolase-like |
decreases activity |
ISO |
benzylparaben results in decreased activity of FAAH protein |
CTD |
PMID:27659731 |
|
NCBI chr 5:134,330,204...134,349,400
Ensembl chr 5:134,331,929...134,348,995
|
|
G |
Fabp4 |
fatty acid binding protein 4 |
increases expression |
ISO |
benzylparaben results in increased expression of FABP4 mRNA |
CTD |
PMID:22956630 PMID:27659731 |
|
NCBI chr 2:93,792,666...93,797,267
Ensembl chr 2:93,792,601...93,797,305
|
|
G |
Fasn |
fatty acid synthase |
increases expression |
ISO |
benzylparaben results in increased expression of FASN mRNA |
CTD |
PMID:22956630 |
|
NCBI chr10:109,987,735...110,005,901
Ensembl chr10:109,987,735...110,005,901
|
|
G |
Lep |
leptin |
decreases expression increases expression |
ISO |
benzylparaben results in decreased expression of LEP mRNA benzylparaben results in increased expression of LEP mRNA |
CTD |
PMID:22956630 |
|
NCBI chr 4:56,337,695...56,351,818
Ensembl chr 4:56,337,695...56,351,818
|
|
G |
Ncoa2 |
nuclear receptor coactivator 2 |
multiple interactions |
ISO |
benzylparaben inhibits the reaction [afimoxifene inhibits the reaction [ESRRG protein binds to NCOA2 protein]] |
CTD |
PMID:23583298 |
|
NCBI chr 5:5,466,544...5,696,540
Ensembl chr 5:5,616,483...5,694,598
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
increases expression |
ISO |
benzylparaben results in increased expression of NR1I2 mRNA |
CTD |
PMID:31472229 |
|
NCBI chr11:65,022,100...65,058,546
Ensembl chr11:65,022,100...65,058,545
|
|
G |
Nr1i3 |
nuclear receptor subfamily 1, group I, member 3 |
increases activity |
ISO |
benzylparaben results in increased activity of NR1I3 protein |
CTD |
PMID:28927721 |
|
NCBI chr13:89,585,072...89,591,278
Ensembl chr13:89,586,283...89,591,277
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
increases expression |
EXP |
benzylparaben results in increased expression of PPARA mRNA |
CTD |
PMID:31472229 |
|
NCBI chr 7:126,618,872...126,687,282
Ensembl chr 7:126,619,196...126,681,752
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
increases expression increases activity |
ISO |
benzylparaben results in increased expression of PPARG mRNA benzylparaben results in increased activity of PPARG protein |
CTD |
PMID:22956630 PMID:27659731 PMID:28527915 |
|
NCBI chr 4:147,274,055...147,399,383
Ensembl chr 4:147,274,107...147,399,380
|
|
G |
Shbg |
sex hormone binding globulin |
affects binding |
ISO |
benzylparaben binds to SHBG protein |
CTD |
PMID:25349334 |
|
NCBI chr10:56,219,861...56,237,354
Ensembl chr10:56,219,858...56,223,245
|
|
|
G |
A4galt |
alpha 1,4-galactosyltransferase (P blood group) |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of A4GALT mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 7:124,085,832...124,110,440
Ensembl chr 7:124,085,834...124,089,385
|
|
G |
Abcc3 |
ATP binding cassette subfamily C member 3 |
increases expression |
ISO |
butylbenzyl phthalate results in increased expression of ABCC3 mRNA |
CTD |
PMID:26519955 |
|
NCBI chr10:82,047,308...82,116,928
Ensembl chr10:82,047,863...82,117,109
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of ABCG2 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 4:88,765,441...88,890,268
Ensembl chr 4:88,832,178...88,890,621
|
|
G |
Acaca |
acetyl-CoA carboxylase alpha |
multiple interactions |
ISO |
[1-Methyl-3-isobutylxanthine co-treated with butylbenzyl phthalate co-treated with INS protein] results in increased expression of ACACA protein |
CTD |
PMID:26820058 |
|
NCBI chr10:71,519,392...71,719,910
Ensembl chr10:71,536,533...71,719,910
|
|
G |
Acot1 |
acyl-CoA thioesterase 1 |
increases expression |
ISO |
butylbenzyl phthalate results in increased expression of ACOT1 mRNA |
CTD |
PMID:26519955 |
|
NCBI chr 6:107,485,088...107,493,082
Ensembl chr 6:107,485,249...107,493,798
|
|
G |
Adipoq |
adiponectin, C1Q and collagen domain containing |
multiple interactions |
ISO |
[1-Methyl-3-isobutylxanthine co-treated with butylbenzyl phthalate co-treated with INS protein] results in increased expression of ADIPOQ mRNA; [1-Methyl-3-isobutylxanthine co-treated with butylbenzyl phthalate co-treated with INS protein] results in increased expression of ADIPOQ protein; butylbenzyl phthalate promotes the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of ADIPOQ mRNA]; Curcumin inhibits the reaction [butylbenzyl phthalate promotes the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of ADIPOQ mRNA]] butylbenzyl phthalate promotes the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased secretion of ADIPOQ protein]; butylbenzyl phthalate promotes the reaction [[Glucose co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of ADIPOQ protein] |
CTD |
PMID:26820058 PMID:28595985 PMID:31016361 PMID:32407875 |
|
NCBI chr11:81,330,845...81,344,488
Ensembl chr11:81,330,293...81,344,488
|
|
G |
Ahr |
aryl hydrocarbon receptor |
affects localization affects activity increases expression multiple interactions |
ISO |
butylbenzyl phthalate affects the localization of AHR protein butylbenzyl phthalate affects the activity of AHR protein butylbenzyl phthalate results in increased expression of AHR mRNA; butylbenzyl phthalate results in increased expression of AHR protein 3',4'-dimethoxyflavone inhibits the reaction [butylbenzyl phthalate results in increased expression of AHR mRNA]; 3',4'-dimethoxyflavone inhibits the reaction [butylbenzyl phthalate results in increased expression of AHR protein]; AHR mutant form inhibits the reaction [butylbenzyl phthalate results in increased expression of ARNT mRNA]; AHR mutant form inhibits the reaction [butylbenzyl phthalate results in increased expression of ARNT protein]; AHR mutant form inhibits the reaction [butylbenzyl phthalate results in increased expression of CYP1B1 mRNA]; AHR mutant form inhibits the reaction [butylbenzyl phthalate results in increased expression of CYP1B1 protein]; butylbenzyl phthalate binds to and results in increased activity of AHR protein; butylbenzyl phthalate promotes the reaction [AHR protein binds to ARNT protein]; butylbenzyl phthalate promotes the reaction [AHR protein binds to CYP1B1 promoter] |
CTD |
PMID:18294747 PMID:22138065 PMID:23220035 |
|
NCBI chr 6:54,963,990...55,001,806
Ensembl chr 6:54,963,990...55,001,464
|
|
G |
Ak5 |
adenylate kinase 5 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of AK5 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 2:257,671,772...257,864,385
Ensembl chr 2:257,671,772...257,864,385
|
|
G |
Akr1b8 |
aldo-keto reductase family 1, member B8 |
increases expression |
EXP |
butylbenzyl phthalate results in increased expression of AKR1B8 mRNA |
CTD |
PMID:19560483 |
|
NCBI chr 4:61,772,064...61,784,637
Ensembl chr 4:61,771,970...61,828,657
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
increases phosphorylation affects phosphorylation multiple interactions |
ISO EXP |
butylbenzyl phthalate results in increased phosphorylation of AKT1 protein butylbenzyl phthalate affects the phosphorylation of AKT1 protein HDAC6 mutant form inhibits the reaction [butylbenzyl phthalate results in increased phosphorylation of AKT1 protein] |
CTD |
PMID:22552774 PMID:29864457 PMID:31319113 |
|
NCBI chr 6:137,218,398...137,239,970
Ensembl chr 6:137,218,376...137,236,258
|
|
G |
Akt2 |
AKT serine/threonine kinase 2 |
increases phosphorylation |
EXP |
butylbenzyl phthalate results in increased phosphorylation of AKT2 protein |
CTD |
PMID:31319113 |
|
NCBI chr 1:84,400,939...84,451,223
Ensembl chr 1:84,411,726...84,450,162
|
|
G |
Aldh1a1 |
aldehyde dehydrogenase 1 family, member A1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in increased expression of ALDH1A1 mRNA |
CTD |
PMID:30768133 |
|
NCBI chr 1:238,222,689...238,264,381
Ensembl chr 1:238,222,521...238,264,330
|
|
G |
Aldoc |
aldolase, fructose-bisphosphate C |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of ALDOC mRNA |
CTD |
PMID:31199487 |
|
NCBI chr10:65,586,504...65,590,093
Ensembl chr10:65,586,504...65,590,126
|
|
G |
Amh |
anti-Mullerian hormone |
multiple interactions increases expression |
EXP |
[butylbenzyl phthalate co-treated with 4-vinyl-1-cyclohexene dioxide] results in decreased expression of AMH mRNA; [butylbenzyl phthalate co-treated with Dibutyl Phthalate] results in decreased expression of AMH mRNA; butylbenzyl phthalate promotes the reaction [4-vinyl-1-cyclohexene dioxide results in decreased expression of AMH protein] butylbenzyl phthalate results in increased expression of AMH mRNA; butylbenzyl phthalate results in increased expression of AMH protein |
CTD |
PMID:29969652 PMID:31319113 |
|
NCBI chr 7:11,775,155...11,777,503
Ensembl chr 7:11,775,155...11,777,503
|
|
G |
Ar |
androgen receptor |
multiple interactions affects binding affects activity decreases activity |
ISO EXP |
butylbenzyl phthalate inhibits the reaction [Dihydrotestosterone binds to and results in increased activity of AR protein]; butylbenzyl phthalate inhibits the reaction [Dihydrotestosterone results in increased activity of AR protein]; butylbenzyl phthalate inhibits the reaction [Stanozolol binds to and results in increased activity of AR protein] butylbenzyl phthalate binds to AR protein butylbenzyl phthalate affects the activity of AR protein butylbenzyl phthalate results in decreased activity of AR protein |
CTD |
PMID:9846162 PMID:14565775 PMID:15840436 PMID:18294747 PMID:20943248 PMID:28571686 PMID:29162470 |
|
NCBI chr X:67,656,253...67,828,998
Ensembl chr X:67,656,253...67,829,026
|
|
G |
Arnt |
aryl hydrocarbon receptor nuclear translocator |
multiple interactions increases expression |
ISO |
3',4'-dimethoxyflavone inhibits the reaction [butylbenzyl phthalate results in increased expression of ARNT mRNA]; 3',4'-dimethoxyflavone inhibits the reaction [butylbenzyl phthalate results in increased expression of ARNT protein]; AHR mutant form inhibits the reaction [butylbenzyl phthalate results in increased expression of ARNT mRNA]; AHR mutant form inhibits the reaction [butylbenzyl phthalate results in increased expression of ARNT protein]; butylbenzyl phthalate promotes the reaction [AHR protein binds to ARNT protein] butylbenzyl phthalate results in increased expression of ARNT mRNA; butylbenzyl phthalate results in increased expression of ARNT protein |
CTD |
PMID:22138065 |
|
NCBI chr 2:196,594,178...196,651,486
Ensembl chr 2:196,594,303...196,651,179
|
|
G |
Arnt2 |
aryl hydrocarbon receptor nuclear translocator 2 |
multiple interactions decreases expression |
ISO EXP |
1,3-bis(4-hydroxyphenyl)-4-methyl-5-(4-(2-piperidinylethoxy)phenol)-1H-pyrazole inhibits the reaction [butylbenzyl phthalate results in decreased expression of ARNT2 mRNA] [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of ARNT2 mRNA |
CTD |
PMID:21771643 PMID:31199487 |
|
NCBI chr 1:146,399,217...146,556,437
Ensembl chr 1:146,399,217...146,556,171
|
|
G |
Astn1 |
astrotactin 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of ASTN1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr13:76,054,965...76,370,674
Ensembl chr13:76,055,410...76,370,674
|
|
G |
Astn2 |
astrotactin 2 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of ASTN2 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 5:81,179,614...82,168,528
Ensembl chr 5:81,179,605...82,168,427
|
|
G |
Atm |
ATM serine/threonine kinase |
increases expression multiple interactions |
ISO |
butylbenzyl phthalate results in increased expression of ATM protein ATM protein affects the reaction [butylbenzyl phthalate results in increased expression of ZEB1 protein] |
CTD |
PMID:31212022 |
|
NCBI chr 8:58,015,938...58,119,973
Ensembl chr 8:58,015,940...58,120,045
|
|
G |
Atp1a1 |
ATPase Na+/K+ transporting subunit alpha 1 |
increases expression |
EXP |
butylbenzyl phthalate results in increased expression of ATP1A1 mRNA |
CTD |
PMID:19560483 |
|
NCBI chr 2:204,003,742...204,032,023
Ensembl chr 2:204,003,742...204,032,023
|
|
G |
Atp1a3 |
ATPase Na+/K+ transporting subunit alpha 3 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of ATP1A3 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 1:81,852,423...81,881,565
Ensembl chr 1:81,852,429...81,881,549
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of BAX mRNA |
CTD |
PMID:28013214 |
|
NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
|
|
G |
Bcat1 |
branched chain amino acid transaminase 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of BCAT1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 4:179,259,305...179,340,021
Ensembl chr 4:179,259,308...179,339,795
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in increased expression of BCL2 mRNA |
CTD |
PMID:28013214 |
|
NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
|
|
G |
Bend6 |
BEN domain containing 6 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of BEND6 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 9:38,297,253...38,351,312
Ensembl chr 9:38,297,322...38,351,024
|
|
G |
Bmp6 |
bone morphogenetic protein 6 |
decreases expression |
EXP |
butylbenzyl phthalate results in decreased expression of BMP6 mRNA |
CTD |
PMID:19560483 |
|
NCBI chr17:26,955,142...27,112,820
Ensembl chr17:26,955,142...27,112,820
|
|
G |
Bpgm |
bisphosphoglycerate mutase |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of BPGM mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 4:61,912,210...61,940,697
Ensembl chr 4:61,912,210...61,940,696
|
|
G |
Cacng7 |
calcium voltage-gated channel auxiliary subunit gamma 7 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of CACNG7 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 1:64,374,547...64,405,380
Ensembl chr 1:64,374,603...64,405,149
|
|
G |
Cadm3 |
cell adhesion molecule 3 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of CADM3 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr13:91,842,311...91,873,126
Ensembl chr13:91,842,333...91,873,096
|
|
G |
Cadps |
calcium dependent secretion activator |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of CADPS mRNA |
CTD |
PMID:31199487 |
|
NCBI chr15:15,275,489...15,690,575
Ensembl chr15:15,275,541...15,667,778
|
|
G |
Camk4 |
calcium/calmodulin-dependent protein kinase IV |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of CAMK4 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr18:25,746,878...25,975,962
Ensembl chr18:25,749,098...25,965,957
|
|
G |
Casp3 |
caspase 3 |
increases expression multiple interactions |
ISO |
butylbenzyl phthalate results in increased expression of CASP3 protein alternative form [Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with 4-nonylphenol co-treated with 4-tert-octylphenol] results in increased expression of and results in increased activity of CASP3 protein; butylbenzyl phthalate results in increased expression of and results in increased activity of CASP3 protein |
CTD |
PMID:23220035 PMID:29029336 |
|
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
|
|
G |
Casp8 |
caspase 8 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of CASP8 mRNA |
CTD |
PMID:28013214 |
|
NCBI chr 9:65,614,142...65,662,624
Ensembl chr 9:65,614,142...65,662,106
|
|
G |
Cat |
catalase |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of CAT mRNA |
CTD |
PMID:28013214 |
|
NCBI chr 3:93,379,872...93,412,058
Ensembl chr 3:93,379,874...93,412,058
|
|
G |
Ccnd1 |
cyclin D1 |
multiple interactions increases expression |
ISO |
MIR19A mRNA affects the reaction [butylbenzyl phthalate results in increased expression of CCND1 protein]; MIR19B1 mRNA affects the reaction [butylbenzyl phthalate results in increased expression of CCND1 protein]; MIR34A mRNA inhibits the reaction [butylbenzyl phthalate results in increased expression of CCND1 protein] butylbenzyl phthalate results in increased expression of CCND1 mRNA; butylbenzyl phthalate results in increased expression of CCND1 protein |
CTD |
PMID:29864457 PMID:30243731 |
|
NCBI chr 1:218,090,750...218,100,447
Ensembl chr 1:218,090,750...218,100,325
|
|
G |
Ccnd2 |
cyclin D2 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of CCND2 mRNA |
CTD |
PMID:28013214 |
|
NCBI chr 4:159,674,885...159,697,207
Ensembl chr 4:159,674,885...159,697,207
|
|
G |
Cdh1 |
cadherin 1 |
decreases expression |
ISO |
butylbenzyl phthalate results in decreased expression of CDH1 protein |
CTD |
PMID:22552774 |
|
NCBI chr19:38,768,467...38,838,395
Ensembl chr19:38,768,467...38,838,395
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
decreases expression multiple interactions |
ISO |
butylbenzyl phthalate results in decreased expression of CDKN1A mRNA; butylbenzyl phthalate results in decreased expression of CDKN1A protein MIR19A mRNA affects the reaction [butylbenzyl phthalate results in decreased expression of CDKN1A protein]; MIR19B1 mRNA affects the reaction [butylbenzyl phthalate results in decreased expression of CDKN1A protein]; MIR34A mRNA inhibits the reaction [butylbenzyl phthalate results in decreased expression of CDKN1A protein] |
CTD |
PMID:29864457 PMID:30243731 |
|
NCBI chr20:6,348,422...6,358,864
Ensembl chr20:6,351,458...6,358,864
|
|
G |
Cdkn2a |
cyclin-dependent kinase inhibitor 2A |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in increased expression of CDKN2A mRNA |
CTD |
PMID:28013214 |
|
NCBI chr 5:107,823,323...107,832,405
Ensembl chr 5:107,823,330...107,841,175
|
|
G |
Cebpa |
CCAAT/enhancer binding protein alpha |
multiple interactions |
ISO |
[1-Methyl-3-isobutylxanthine co-treated with butylbenzyl phthalate co-treated with INS protein] results in increased expression of CEBPA mRNA; [1-Methyl-3-isobutylxanthine co-treated with butylbenzyl phthalate co-treated with INS protein] results in increased expression of CEBPA protein; butylbenzyl phthalate promotes the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of CEBPA mRNA]; Curcumin inhibits the reaction [butylbenzyl phthalate promotes the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of CEBPA mRNA]] |
CTD |
PMID:26820058 PMID:28595985 |
|
NCBI chr 1:91,363,492...91,366,164
Ensembl chr 1:91,363,492...91,366,164
|
|
G |
Celsr3 |
cadherin, EGF LAG seven-pass G-type receptor 3 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of CELSR3 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 8:117,620,293...117,648,034
Ensembl chr 8:117,620,317...117,648,028
|
|
G |
Cfd |
complement factor D |
multiple interactions |
ISO |
[1-Methyl-3-isobutylxanthine co-treated with butylbenzyl phthalate co-treated with INS protein] results in increased expression of CFD mRNA |
CTD |
PMID:26820058 |
|
NCBI chr 7:12,634,216...12,635,939
Ensembl chr 7:12,634,216...12,635,943
|
|
G |
Cga |
glycoprotein hormones, alpha polypeptide |
multiple interactions |
ISO |
butylbenzyl phthalate inhibits the reaction [CGA protein results in increased secretion of Dinoprostone]; butylbenzyl phthalate inhibits the reaction [CGA protein results in increased secretion of Progesterone] |
CTD |
PMID:25016925 |
|
NCBI chr 5:50,362,491...50,393,368
Ensembl chr 5:50,381,244...50,393,367
|
|
G |
Chga |
chromogranin A |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of CHGA mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 6:126,434,226...126,445,569
Ensembl chr 6:126,434,226...126,445,568
|
|
G |
Chgb |
chromogranin B |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of CHGB mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 3:125,428,050...125,441,601
Ensembl chr 3:125,428,260...125,441,594
|
|
G |
Cited1 |
Cbp/p300-interacting transactivator with Glu/Asp-rich carboxy-terminal domain 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of CITED1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr X:72,128,996...72,133,692
Ensembl chr X:72,128,994...72,133,692
|
|
G |
Clstn3 |
calsyntenin 3 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of CLSTN3 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 4:157,044,736...157,078,013
Ensembl chr 4:157,043,925...157,078,130
|
|
G |
Cntnap1 |
contactin associated protein 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of CNTNAP1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr10:89,087,904...89,103,615
Ensembl chr10:89,089,646...89,103,614
|
|
G |
Comt |
catechol-O-methyltransferase |
decreases expression multiple interactions |
ISO |
butylbenzyl phthalate results in decreased expression of COMT mRNA fulvestrant inhibits the reaction [butylbenzyl phthalate results in decreased expression of COMT mRNA] |
CTD |
PMID:24040167 |
|
NCBI chr11:86,715,981...86,735,630
Ensembl chr11:86,715,981...86,735,622
|
|
G |
Crmp1 |
collapsin response mediator protein 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of CRMP1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr14:78,266,931...78,312,777
Ensembl chr14:78,266,931...78,308,933
|
|
G |
Ctnnb1 |
catenin beta 1 |
affects localization increases acetylation multiple interactions |
ISO |
butylbenzyl phthalate affects the localization of CTNNB1 protein butylbenzyl phthalate results in increased acetylation of CTNNB1 protein HDAC6 mutant form inhibits the reaction [butylbenzyl phthalate affects the localization of CTNNB1 protein]; trichostatin A inhibits the reaction [butylbenzyl phthalate affects the localization of CTNNB1 protein] |
CTD |
PMID:22552774 PMID:27923775 |
|
NCBI chr 8:129,601,511...129,628,378
Ensembl chr 8:129,617,812...129,627,372
|
|
G |
Cyp11a1 |
cytochrome P450, family 11, subfamily a, polypeptide 1 |
increases expression multiple interactions |
EXP ISO |
butylbenzyl phthalate results in increased expression of CYP11A1 mRNA; butylbenzyl phthalate results in increased expression of CYP11A1 protein [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of CYP11A1 mRNA; [Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with 4-nonylphenol co-treated with 4-tert-octylphenol] results in decreased expression of CYP11A1 mRNA; [Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diethyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate co-treated with diisononyl phthalate] results in decreased expression of CYP11A1 mRNA |
CTD |
PMID:26472102 PMID:28013214 PMID:29029336 PMID:30802670 PMID:31319113 |
|
NCBI chr 8:62,798,317...62,809,848
Ensembl chr 8:62,779,875...62,809,893
|
|
G |
Cyp17a1 |
cytochrome P450, family 17, subfamily a, polypeptide 1 |
decreases expression multiple interactions |
EXP ISO |
butylbenzyl phthalate results in decreased expression of CYP17A1 mRNA [Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with 4-nonylphenol co-treated with 4-tert-octylphenol] results in increased expression of CYP17A1 mRNA; [Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diethyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate co-treated with diisononyl phthalate] results in decreased expression of CYP17A1 mRNA |
CTD |
PMID:26472102 PMID:29029336 PMID:30802670 |
|
NCBI chr 1:266,422,127...266,429,947
Ensembl chr 1:266,422,132...266,428,239
|
|
G |
Cyp19a1 |
cytochrome P450, family 19, subfamily a, polypeptide 1 |
multiple interactions decreases expression decreases activity |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of CYP19A1 mRNA; [Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with 4-nonylphenol co-treated with 4-tert-octylphenol] results in decreased expression of CYP19A1 mRNA; [Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with 4-nonylphenol co-treated with 4-tert-octylphenol] results in decreased expression of CYP19A1 protein butylbenzyl phthalate results in decreased expression of CYP19A1 mRNA; butylbenzyl phthalate results in decreased expression of CYP19A1 protein butylbenzyl phthalate results in decreased activity of CYP19A1 protein |
CTD |
PMID:27825933 PMID:28013214 PMID:29029336 |
|
NCBI chr 8:58,744,849...58,772,408
Ensembl chr 8:58,744,849...58,772,408
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
increases expression decreases activity |
ISO EXP |
butylbenzyl phthalate results in increased expression of CYP1A1 protein butylbenzyl phthalate results in decreased activity of CYP1A1 protein |
CTD |
PMID:22138065 PMID:27432241 |
|
NCBI chr 8:62,472,087...62,478,122
Ensembl chr 8:62,472,095...62,478,147
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
decreases activity |
EXP |
butylbenzyl phthalate results in decreased activity of CYP1A2 protein |
CTD |
PMID:27432241 |
|
NCBI chr 8:62,451,360...62,458,244
Ensembl chr 8:62,451,329...62,458,301
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
multiple interactions increases expression |
ISO |
3',4'-dimethoxyflavone inhibits the reaction [butylbenzyl phthalate results in increased expression of CYP1B1 mRNA]; 3',4'-dimethoxyflavone inhibits the reaction [butylbenzyl phthalate results in increased expression of CYP1B1 protein]; AHR mutant form inhibits the reaction [butylbenzyl phthalate results in increased expression of CYP1B1 mRNA]; AHR mutant form inhibits the reaction [butylbenzyl phthalate results in increased expression of CYP1B1 protein]; butylbenzyl phthalate promotes the reaction [AHR protein binds to CYP1B1 promoter] butylbenzyl phthalate results in increased expression of CYP1B1 mRNA; butylbenzyl phthalate results in increased expression of CYP1B1 protein |
CTD |
PMID:22138065 |
|
NCBI chr 6:2,308,179...2,316,739
Ensembl chr 6:2,307,808...2,316,722
|
|
G |
Cyp27a1 |
cytochrome P450, family 27, subfamily a, polypeptide 1 |
increases expression |
EXP |
butylbenzyl phthalate results in increased expression of CYP27A1 mRNA |
CTD |
PMID:26472102 |
|
NCBI chr 9:81,968,285...81,998,213
Ensembl chr 9:81,968,332...81,998,169
|
|
G |
Cyp2b1 |
cytochrome P450, family 2, subfamily b, polypeptide 1 |
increases expression decreases activity |
ISO EXP |
butylbenzyl phthalate results in increased expression of CYP2B10 mRNA butylbenzyl phthalate results in decreased activity of CYP2B1 protein |
CTD |
PMID:26519955 PMID:27432241 |
|
NCBI chr 7:99,142,431...99,183,540
Ensembl chr 7:99,142,450...99,181,783
|
|
G |
Cyp2c11 |
cytochrome P450, subfamily 2, polypeptide 11 |
decreases activity |
EXP |
butylbenzyl phthalate results in decreased activity of CYP2C11 protein |
CTD |
PMID:27432241 |
|
NCBI chr 1:257,676,172...258,004,428
Ensembl chr 1:257,970,345...258,004,434
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
decreases activity |
EXP |
butylbenzyl phthalate results in decreased activity of CYP2E1 protein |
CTD |
PMID:27432241 |
|
NCBI chr 1:213,511,892...213,522,195
Ensembl chr 1:213,511,874...213,535,542
|
|
G |
Cyp3a62 |
cytochrome P450, family 3, subfamily a, polypeptide 62 |
decreases activity |
EXP |
butylbenzyl phthalate results in decreased activity of CYP3A62 protein |
CTD |
PMID:27432241 |
|
NCBI chr12:18,679,809...18,709,397
Ensembl chr12:18,678,594...18,709,397
|
|
G |
Cyp51 |
cytochrome P450, family 51 |
decreases expression |
EXP |
butylbenzyl phthalate results in decreased expression of CYP51 mRNA |
CTD |
PMID:26472102 |
|
NCBI chr 4:27,175,564...27,194,018
Ensembl chr 4:27,175,243...27,194,018
|
|
G |
Dclk3 |
doublecortin-like kinase 3 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of DCLK3 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 8:119,691,567...119,744,484
Ensembl chr 8:119,691,388...119,744,506
|
|
G |
Ddc |
dopa decarboxylase |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of DDC mRNA |
CTD |
PMID:31199487 |
|
NCBI chr14:91,905,919...91,996,816
Ensembl chr14:91,905,919...91,996,774
|
|
G |
Dock3 |
dedicator of cyto-kinesis 3 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of DOCK3 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 8:115,627,282...115,982,260
Ensembl chr 8:115,629,583...115,981,910
|
|
G |
Dpf1 |
double PHD fingers 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of DPF1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 1:87,248,448...87,258,070
Ensembl chr 1:87,248,489...87,258,070
|
|
G |
Dync1i1 |
dynein cytoplasmic 1 intermediate chain 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of DYNC1I1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 4:30,807,755...31,121,097
Ensembl chr 4:30,807,879...31,121,090
|
|
G |
Ebp |
EBP, cholestenol delta-isomerase |
decreases expression |
EXP |
butylbenzyl phthalate results in decreased expression of EBP mRNA |
CTD |
PMID:26472102 |
|
NCBI chr X:15,049,394...15,055,782
Ensembl chr X:15,049,462...15,055,781
|
|
G |
Ece2 |
endothelin-converting enzyme 2 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of ECE2 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr11:83,948,896...83,985,429
Ensembl chr11:83,948,230...83,964,055
|
|
G |
Edn1 |
endothelin 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of EDN1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr17:22,136,814...22,143,745
Ensembl chr17:22,137,324...22,143,324
|
|
G |
Egfr |
epidermal growth factor receptor |
multiple interactions increases phosphorylation |
ISO |
fulvestrant inhibits the reaction [butylbenzyl phthalate results in increased phosphorylation of EGFR protein] |
CTD |
PMID:22552774 |
|
NCBI chr14:99,919,485...100,104,136
Ensembl chr14:99,919,485...100,098,796
|
|
G |
Elmod1 |
ELMO domain containing 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of ELMOD1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 8:58,486,078...58,542,884
Ensembl chr 8:58,486,078...58,542,844
|
|
G |
Emx2 |
empty spiracles homeobox 2 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of EMX2 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 1:280,633,938...280,640,946
Ensembl chr 1:280,633,938...280,640,946
|
|
G |
Epdr1 |
ependymin related 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of EPDR1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr17:47,397,558...47,422,183
Ensembl chr17:47,397,558...47,422,182
|
|
G |
Espn |
espin |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of ESPN mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 5:169,293,356...169,331,338
Ensembl chr 5:169,293,904...169,331,163
|
|
G |
Esr1 |
estrogen receptor 1 |
multiple interactions decreases expression increases activity affects binding decreases methylation |
ISO |
butylbenzyl phthalate binds to and results in increased activity of ESR1 protein; butylbenzyl phthalate inhibits the reaction [Estradiol results in increased activity of ESR1 protein]; Oxygen deficiency promotes the reaction [butylbenzyl phthalate results in decreased expression of ESR1 mRNA]; Oxygen deficiency promotes the reaction [butylbenzyl phthalate results in decreased expression of ESR1 protein]; Tamoxifen inhibits the reaction [butylbenzyl phthalate binds to and results in increased activity of ESR1 protein] butylbenzyl phthalate results in decreased expression of ESR1 mRNA; butylbenzyl phthalate results in decreased expression of ESR1 protein butylbenzyl phthalate results in increased activity of ESR1 protein [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of ESR1 mRNA butylbenzyl phthalate binds to ESR1 protein butylbenzyl phthalate results in decreased methylation of ESR1 gene; butylbenzyl phthalate results in decreased methylation of ESR1 promoter |
CTD |
PMID:15840436 PMID:16326419 PMID:19913605 PMID:20822795 PMID:22467034 PMID:22949852 PMID:28013214 PMID:28571686 PMID:29162470 PMID:30851587 |
|
NCBI chr 1:41,192,029...41,594,799
Ensembl chr 1:41,192,824...41,594,796
|
|
G |
Esr2 |
estrogen receptor 2 |
multiple interactions increases activity affects binding |
ISO |
butylbenzyl phthalate binds to and results in decreased activity of ESR2 protein; butylbenzyl phthalate binds to and results in increased activity of ESR2 protein; butylbenzyl phthalate inhibits the reaction [Estradiol results in increased activity of ESR2 protein] butylbenzyl phthalate results in increased activity of ESR2 protein butylbenzyl phthalate binds to ESR2 protein |
CTD |
PMID:15840436 PMID:19913605 PMID:28571686 |
|
NCBI chr 6:99,163,953...99,214,711
Ensembl chr 6:99,164,357...99,214,251
|
|
G |
Fabp4 |
fatty acid binding protein 4 |
increases expression multiple interactions |
ISO |
butylbenzyl phthalate results in increased expression of FABP4 mRNA [1-Methyl-3-isobutylxanthine co-treated with butylbenzyl phthalate co-treated with INS protein] results in increased expression of FABP4 mRNA |
CTD |
PMID:24155963 PMID:26820058 PMID:27923775 |
|
NCBI chr 2:93,792,666...93,797,267
Ensembl chr 2:93,792,601...93,797,305
|
|
G |
Fabp5 |
fatty acid binding protein 5 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of FABP5 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 2:93,981,662...93,985,322
Ensembl chr 2:93,981,656...93,985,378
|
|
G |
Fam163a |
family with sequence similarity 163, member A |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of FAM163A mRNA |
CTD |
PMID:31199487 |
|
NCBI chr13:73,741,674...73,820,114
Ensembl chr13:73,741,679...73,819,896
|
|
G |
Fasn |
fatty acid synthase |
multiple interactions |
ISO |
[1-Methyl-3-isobutylxanthine co-treated with butylbenzyl phthalate co-treated with INS protein] results in increased expression of FASN mRNA; [1-Methyl-3-isobutylxanthine co-treated with butylbenzyl phthalate co-treated with INS protein] results in increased expression of FASN protein |
CTD |
PMID:26820058 |
|
NCBI chr10:109,987,735...110,005,901
Ensembl chr10:109,987,735...110,005,901
|
|
G |
Fez1 |
fasciculation and elongation protein zeta 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of FEZ1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 8:39,305,128...39,350,270
Ensembl chr 8:39,305,128...39,350,270
|
|
G |
Fgfr2 |
fibroblast growth factor receptor 2 |
decreases expression |
EXP |
butylbenzyl phthalate results in decreased expression of FGFR2 mRNA |
CTD |
PMID:26472102 |
|
NCBI chr 1:200,590,951...200,696,946
Ensembl chr 1:200,590,953...200,696,928
|
|
G |
Fkbp1b |
FKBP prolyl isomerase 1B |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of FKBP1B mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 6:29,975,863...29,987,252
Ensembl chr 6:29,977,797...29,987,451
|
|
G |
Flg |
filaggrin |
multiple interactions |
ISO |
[FLG gene polymorphism affects the susceptibility to butylbenzyl phthalate] which affects the abundance of mono-benzyl phthalate |
CTD |
PMID:24380925 |
|
NCBI chr 2:193,565,401...193,574,297
|
|
G |
Foxo1 |
forkhead box O1 |
multiple interactions |
ISO |
butylbenzyl phthalate results in increased expression of and results in increased acetylation of FOXO1 protein |
CTD |
PMID:27923775 |
|
NCBI chr 2:141,451,234...141,527,016
Ensembl chr 2:141,451,234...141,527,016
|
|
G |
Fsd2 |
fibronectin type III and SPRY domain containing 2 |
increases expression decreases expression |
EXP |
butylbenzyl phthalate results in increased expression of FSD2 mRNA butylbenzyl phthalate results in decreased expression of FSD2 mRNA |
CTD |
PMID:26472102 |
|
NCBI chr 1:143,364,867...143,398,123
Ensembl chr 1:143,364,867...143,398,093
|
|
G |
Fshb |
follicle stimulating hormone subunit beta |
multiple interactions increases expression |
EXP |
butylbenzyl phthalate promotes the reaction [Dibutyl Phthalate results in increased expression of FSHB protein] butylbenzyl phthalate results in increased expression of FSHB protein |
CTD |
PMID:29969652 |
|
NCBI chr 3:98,088,321...98,092,131
Ensembl chr 3:98,088,324...98,092,131
|
|
G |
Fshr |
follicle stimulating hormone receptor |
multiple interactions increases expression |
ISO EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of FSHR mRNA butylbenzyl phthalate results in increased expression of FSHR mRNA; butylbenzyl phthalate results in increased expression of FSHR protein |
CTD |
PMID:28013214 PMID:31319113 |
|
NCBI chr 6:12,796,383...12,997,817
Ensembl chr 6:12,796,383...12,997,817
|
|
G |
Fxyd7 |
FXYD domain-containing ion transport regulator 7 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of FXYD7 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 1:89,474,601...89,484,069
Ensembl chr 1:89,474,601...89,483,988
|
|
G |
Gabpb1 |
GA binding protein transcription factor subunit beta 1 |
decreases expression |
ISO |
butylbenzyl phthalate results in decreased expression of GABPB1 mRNA |
CTD |
PMID:26520405 |
|
NCBI chr 3:119,091,739...119,135,391
Ensembl chr 3:119,091,744...119,135,391
|
|
G |
Gfra3 |
GDNF family receptor alpha 3 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of GFRA3 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr18:27,491,860...27,520,133
Ensembl chr18:27,491,845...27,520,295
|
|
G |
Gfra4 |
GDNF family receptor alpha 4 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of GFRA4 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 3:123,573,394...123,582,431
Ensembl chr 3:123,578,997...123,581,518
|
|
G |
Ggta1 |
glycoprotein alpha-galactosyltransferase 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of GGTA1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 3:14,614,099...14,701,185
Ensembl chr 3:14,614,122...14,644,951
|
|
G |
Gng2 |
G protein subunit gamma 2 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of GNG2 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr15:4,748,242...4,853,555
Ensembl chr15:4,850,122...4,853,555
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of GPX1 mRNA |
CTD |
PMID:28013214 |
|
NCBI chr 8:117,117,430...117,118,528
Ensembl chr 8:117,117,430...117,118,522
|
|
G |
Grb14 |
growth factor receptor bound protein 14 |
increases expression |
EXP |
butylbenzyl phthalate results in increased expression of GRB14 mRNA |
CTD |
PMID:15728792 |
|
NCBI chr 3:50,937,403...51,054,447
Ensembl chr 3:50,937,669...51,054,378
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
multiple interactions increases phosphorylation |
ISO |
HDAC6 mutant form inhibits the reaction [butylbenzyl phthalate results in increased phosphorylation of GSK3B protein] |
CTD |
PMID:22552774 |
|
NCBI chr11:65,060,884...65,208,842
Ensembl chr11:65,066,235...65,209,268
|
|
G |
Gsr |
glutathione-disulfide reductase |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of GSR mRNA |
CTD |
PMID:28013214 |
|
NCBI chr16:62,197,617...62,239,987
Ensembl chr16:62,197,617...62,241,361
|
|
G |
Gsta3 |
glutathione S-transferase alpha 3 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of GSTA3 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 9:27,357,490...27,417,023
Ensembl chr 9:27,402,381...27,417,023
|
|
G |
Hdac6 |
histone deacetylase 6 |
multiple interactions increases response to substance increases expression |
ISO |
[butylbenzyl phthalate promotes the reaction [TFAP2A protein binds to HDAC6 promoter]] which results in increased expression of HDAC6 mRNA; butylbenzyl phthalate promotes the reaction [TFAP2A protein binds to HDAC6 promoter]; HDAC6 mutant form inhibits the reaction [butylbenzyl phthalate affects the localization of CTNNB1 protein]; HDAC6 mutant form inhibits the reaction [butylbenzyl phthalate promotes the reaction [[TCF4 protein binds to LEF1 protein] which binds to VIM protein]]; HDAC6 mutant form inhibits the reaction [butylbenzyl phthalate results in decreased expression of KRT7 protein]; HDAC6 mutant form inhibits the reaction [butylbenzyl phthalate results in increased expression of VIM protein]; HDAC6 mutant form inhibits the reaction [butylbenzyl phthalate results in increased phosphorylation of AKT1 protein]; HDAC6 mutant form inhibits the reaction [butylbenzyl phthalate results in increased phosphorylation of GSK3B protein]; TFAP2A mutant form inhibits the reaction [butylbenzyl phthalate results in increased expression of HDAC6 protein] HDAC6 results in increased susceptibility to butylbenzyl phthalate butylbenzyl phthalate results in increased expression of HDAC6 mRNA; butylbenzyl phthalate results in increased expression of HDAC6 protein |
CTD |
PMID:22552774 |
|
NCBI chr X:15,295,372...15,316,673
Ensembl chr X:15,295,473...15,316,671
|
|
G |
Hey1 |
hes-related family bHLH transcription factor with YRPW motif 1 |
decreases expression |
EXP |
butylbenzyl phthalate results in decreased expression of HEY1 mRNA |
CTD |
PMID:26472102 |
|
NCBI chr 2:95,320,147...95,322,701
Ensembl chr 2:95,320,283...95,322,696
|
|
G |
Hnf1a |
HNF1 homeobox A |
decreases expression |
EXP |
butylbenzyl phthalate results in decreased expression of HNF1A mRNA |
CTD |
PMID:15728792 |
|
NCBI chr12:47,407,811...47,433,342
Ensembl chr12:47,407,811...47,433,342
|
|
G |
Hoxb8 |
homeo box B8 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of HOXB8 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr10:84,131,484...84,133,874
Ensembl chr10:84,131,495...84,133,246
|
|
G |
Hoxd3 |
homeo box D3 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of HOXD3 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 3:61,650,569...61,670,285
Ensembl chr 3:61,658,245...61,670,282
|
|
G |
Hsd11b1 |
hydroxysteroid 11-beta dehydrogenase 1 |
increases expression |
EXP |
butylbenzyl phthalate results in increased expression of HSD11B1 protein |
CTD |
PMID:31319113 |
|
NCBI chr13:111,946,626...111,996,536
Ensembl chr13:111,926,442...111,972,603
|
|
G |
Hsd17b11 |
hydroxysteroid (17-beta) dehydrogenase 11 |
increases expression |
EXP |
butylbenzyl phthalate results in increased expression of HSD17B11 mRNA |
CTD |
PMID:26472102 |
|
NCBI chr14:7,054,724...7,104,567
Ensembl chr14:7,073,445...7,104,566
|
|
G |
Hsd17b8 |
hydroxysteroid (17-beta) dehydrogenase 8 |
increases expression |
EXP |
butylbenzyl phthalate results in increased expression of HSD17B8 mRNA |
CTD |
PMID:19560483 PMID:26472102 |
|
NCBI chr20:3,817,212...3,819,316
Ensembl chr20:3,817,179...3,819,235
|
|
G |
Hsd3b1 |
hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1 |
multiple interactions increases expression |
ISO EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of HSD3B1 mRNA butylbenzyl phthalate results in increased expression of HSD3B1 mRNA; butylbenzyl phthalate results in increased expression of HSD3B1 protein |
CTD |
PMID:28013214 PMID:31319113 |
|
|
|
G |
Hspa12a |
heat shock protein family A (Hsp70) member 12A |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of HSPA12A mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 1:279,946,809...280,104,366
Ensembl chr 1:279,946,811...280,015,358
|
|
G |
Id1 |
inhibitor of DNA binding 1, HLH protein |
decreases expression |
EXP |
butylbenzyl phthalate results in decreased expression of ID1 mRNA |
CTD |
PMID:26472102 |
|
NCBI chr 3:148,214,623...148,216,715
Ensembl chr 3:148,215,540...148,216,718
|
|
G |
Ido2 |
indoleamine 2,3-dioxygenase 2 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of IDO2 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr16:72,232,852...72,291,227
Ensembl chr16:72,268,943...72,289,156
|
|
G |
Igf1 |
insulin-like growth factor 1 |
decreases expression |
EXP |
butylbenzyl phthalate results in decreased expression of IGF1 mRNA |
CTD |
PMID:26472102 |
|
NCBI chr 7:28,412,123...28,491,815
Ensembl chr 7:28,412,198...28,486,609
|
|
G |
Igfbp7 |
insulin-like growth factor binding protein 7 |
decreases expression |
EXP |
butylbenzyl phthalate results in decreased expression of IGFBP7 mRNA |
CTD |
PMID:19560483 |
|
NCBI chr14:33,010,300...33,070,193
Ensembl chr14:33,010,300...33,070,190
|
|
G |
Inha |
inhibin subunit alpha |
decreases expression |
EXP |
butylbenzyl phthalate results in decreased expression of INHA mRNA |
CTD |
PMID:26472102 |
|
NCBI chr 9:82,700,482...82,703,383
Ensembl chr 9:82,700,468...82,703,400
|
|
G |
Ins2 |
insulin 2 |
multiple interactions |
ISO |
[1-Methyl-3-isobutylxanthine co-treated with butylbenzyl phthalate co-treated with INS protein] affects the abundance of diphosphoric acid analog; [1-Methyl-3-isobutylxanthine co-treated with butylbenzyl phthalate co-treated with INS protein] results in increased abundance of carbamic acid analog; [1-Methyl-3-isobutylxanthine co-treated with butylbenzyl phthalate co-treated with INS protein] results in increased abundance of Cholesterol analog; [1-Methyl-3-isobutylxanthine co-treated with butylbenzyl phthalate co-treated with INS protein] results in increased abundance of Cystathionine analog; [1-Methyl-3-isobutylxanthine co-treated with butylbenzyl phthalate co-treated with INS protein] results in increased abundance of Desmosterol analog; [1-Methyl-3-isobutylxanthine co-treated with butylbenzyl phthalate co-treated with INS protein] results in increased abundance of ethylamine analog; [1-Methyl-3-isobutylxanthine co-treated with butylbenzyl phthalate co-treated with INS protein] results in increased abundance of Glycine analog; [1-Methyl-3-isobutylxanthine co-treated with butylbenzyl phthalate co-treated with INS protein] results in increased abundance of Inositol analog; [1-Methyl-3-isobutylxanthine co-treated with butylbenzyl phthalate co-treated with INS protein] results in increased abundance of methylphosphate analog; [1-Methyl-3-isobutylxanthine co-treated with butylbenzyl phthalate co-treated with INS protein] results in increased abundance of monoethyl phosphate analog; [1-Methyl-3-isobutylxanthine co-treated with butylbenzyl phthalate co-treated with INS protein] results in increased abundance of n-butylamine analog; [1-Methyl-3-isobutylxanthine co-treated with butylbenzyl phthalate co-treated with INS protein] results in increased abundance of Palmitic Acid analog; [1-Methyl-3-isobutylxanthine co-treated with butylbenzyl phthalate co-treated with INS protein] results in increased abundance of phosphoric acid analog; [1-Methyl-3-isobutylxanthine co-treated with butylbenzyl phthalate co-treated with INS protein] results in increased abundance of Pyrrolidonecarboxylic Acid analog; [1-Methyl-3-isobutylxanthine co-treated with butylbenzyl phthalate co-treated with INS protein] results in increased abundance of sebacic acid analog; [1-Methyl-3-isobutylxanthine co-treated with butylbenzyl phthalate co-treated with INS protein] results in increased abundance of stearic acid analog; [1-Methyl-3-isobutylxanthine co-treated with butylbenzyl phthalate co-treated with INS protein] results in increased abundance of undecane analog; [1-Methyl-3-isobutylxanthine co-treated with butylbenzyl phthalate co-treated with INS protein] results in increased expression of ACACA protein; [1-Methyl-3-isobutylxanthine co-treated with butylbenzyl phthalate co-treated with INS protein] results in increased expression of ADIPOQ mRNA; [1-Methyl-3-isobutylxanthine co-treated with butylbenzyl phthalate co-treated with INS protein] results in increased expression of ADIPOQ protein; [1-Methyl-3-isobutylxanthine co-treated with butylbenzyl phthalate co-treated with INS protein] results in increased expression of CEBPA mRNA; [1-Methyl-3-isobutylxanthine co-treated with butylbenzyl phthalate co-treated with INS protein] results in increased expression of CEBPA protein; [1-Methyl-3-isobutylxanthine co-treated with butylbenzyl phthalate co-treated with INS protein] results in increased expression of CFD mRNA; [1-Methyl-3-isobutylxanthine co-treated with butylbenzyl phthalate co-treated with INS protein] results in increased expression of FABP4 mRNA; [1-Methyl-3-isobutylxanthine co-treated with butylbenzyl phthalate co-treated with INS protein] results in increased expression of FASN mRNA; [1-Methyl-3-isobutylxanthine co-treated with butylbenzyl phthalate co-treated with INS protein] results in increased expression of FASN protein; [1-Methyl-3-isobutylxanthine co-treated with butylbenzyl phthalate co-treated with INS protein] results in increased expression of LPL mRNA; [1-Methyl-3-isobutylxanthine co-treated with butylbenzyl phthalate co-treated with INS protein] results in increased expression of PLIN1 protein; [1-Methyl-3-isobutylxanthine co-treated with butylbenzyl phthalate co-treated with INS protein] results in increased expression of PPARG mRNA; [1-Methyl-3-isobutylxanthine co-treated with butylbenzyl phthalate co-treated with INS protein] results in increased expression of PPARG protein; butylbenzyl phthalate promotes the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased abundance of Triglycerides]; butylbenzyl phthalate promotes the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of ADIPOQ mRNA]; butylbenzyl phthalate promotes the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of CEBPA mRNA]; butylbenzyl phthalate promotes the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of PPARG mRNA]; butylbenzyl phthalate promotes the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of TNF mRNA]; Curcumin inhibits the reaction [butylbenzyl phthalate promotes the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased abundance of Triglycerides]]; Curcumin inhibits the reaction [butylbenzyl phthalate promotes the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of ADIPOQ mRNA]]; Curcumin inhibits the reaction [butylbenzyl phthalate promotes the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of CEBPA mRNA]]; Curcumin inhibits the reaction [butylbenzyl phthalate promotes the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of PPARG mRNA]]; Curcumin inhibits the reaction [butylbenzyl phthalate promotes the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of TNF mRNA]] butylbenzyl phthalate promotes the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in decreased secretion of TNFRSF11B protein]; butylbenzyl phthalate promotes the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased secretion of ADIPOQ protein]; butylbenzyl phthalate promotes the reaction [[Glucose co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of ADIPOQ protein] |
CTD |
PMID:26820058 PMID:28595985 PMID:31016361 PMID:32407875 |
|
NCBI chr 1:215,856,967...215,858,034
Ensembl chr 1:215,856,971...215,858,034
|
|
G |
Insig1 |
insulin induced gene 1 |
decreases expression |
EXP |
butylbenzyl phthalate results in decreased expression of INSIG1 mRNA |
CTD |
PMID:15728792 |
|
NCBI chr 4:342,302...350,515
Ensembl chr 4:342,302...350,515
|
|
G |
Insl3 |
insulin-like 3 |
decreases expression |
EXP |
butylbenzyl phthalate results in decreased expression of INSL3 mRNA |
CTD |
PMID:14687758 PMID:16102138 PMID:18411233 |
|
NCBI chr16:20,120,753...20,122,702
Ensembl chr16:20,121,352...20,122,696
|
|
G |
Kif5c |
kinesin family member 5C |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of KIF5C mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 3:35,014,157...35,257,417
Ensembl chr 3:35,014,538...35,257,407
|
|
G |
Krt7 |
keratin 7 |
decreases expression multiple interactions |
ISO |
butylbenzyl phthalate results in decreased expression of KRT7 protein HDAC6 mutant form inhibits the reaction [butylbenzyl phthalate results in decreased expression of KRT7 protein] |
CTD |
PMID:22552774 |
|
NCBI chr 7:143,059,731...143,075,907
Ensembl chr 7:143,059,764...143,075,907
|
|
G |
L1cam |
L1 cell adhesion molecule |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of L1CAM mRNA |
CTD |
PMID:31199487 |
|
NCBI chr X:156,901,244...156,928,064
Ensembl chr X:156,909,913...156,928,057
|
|
G |
Lamp3 |
lysosomal-associated membrane protein 3 |
decreases expression |
ISO |
butylbenzyl phthalate results in decreased expression of LAMP3 mRNA |
CTD |
PMID:20678512 |
|
NCBI chr11:84,930,965...85,000,694
Ensembl chr11:84,972,132...85,000,681
|
|
G |
Lcn2 |
lipocalin 2 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of LCN2 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 3:11,414,189...11,417,534
Ensembl chr 3:11,414,186...11,417,546
|
|
G |
Ldlr |
low density lipoprotein receptor |
decreases expression |
EXP |
butylbenzyl phthalate results in decreased expression of LDLR mRNA |
CTD |
PMID:15728792 |
|
NCBI chr 8:22,750,425...22,773,305
Ensembl chr 8:22,750,336...22,774,903
|
|
G |
Lef1 |
lymphoid enhancer binding factor 1 |
multiple interactions |
ISO |
butylbenzyl phthalate promotes the reaction [[TCF4 protein binds to LEF1 protein] which binds to VIM protein]; HDAC6 mutant form inhibits the reaction [butylbenzyl phthalate promotes the reaction [[TCF4 protein binds to LEF1 protein] which binds to VIM protein]]; trichostatin A inhibits the reaction [butylbenzyl phthalate promotes the reaction [[TCF4 protein binds to LEF1 protein] which binds to VIM protein]] |
CTD |
PMID:22552774 |
|
NCBI chr 2:236,232,115...236,345,061
Ensembl chr 2:236,233,239...236,345,056
|
|
G |
Lhcgr |
luteinizing hormone/choriogonadotropin receptor |
decreases expression increases expression |
EXP |
butylbenzyl phthalate results in decreased expression of LHCGR mRNA butylbenzyl phthalate results in increased expression of LHCGR mRNA; butylbenzyl phthalate results in increased expression of LHCGR protein |
CTD |
PMID:15728792 PMID:31319113 |
|
NCBI chr 6:12,493,182...12,554,482
Ensembl chr 6:12,493,943...12,554,439
|
|
G |
Lonrf2 |
LON peptidase N-terminal domain and ring finger 2 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of LONRF2 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 9:45,468,001...45,506,448
Ensembl chr 9:45,466,688...45,505,767
|
|
G |
Lpl |
lipoprotein lipase |
multiple interactions |
ISO |
[1-Methyl-3-isobutylxanthine co-treated with butylbenzyl phthalate co-treated with INS protein] results in increased expression of LPL mRNA; [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in increased expression of LPL mRNA |
CTD |
PMID:26820058 PMID:30768133 |
|
NCBI chr16:22,537,687...22,561,487
Ensembl chr16:22,537,056...22,561,496
|
|
G |
Lrrc4b |
leucine rich repeat containing 4B |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of LRRC4B mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 1:100,434,418...100,468,914
Ensembl chr 1:100,447,998...100,468,868
|
|
G |
Lynx1 |
Ly6/neurotoxin 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of LYNX1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 7:115,982,877...115,988,121
Ensembl chr 7:115,982,876...115,988,090
|
|
G |
Map6 |
microtubule-associated protein 6 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of MAP6 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 1:164,225,776...164,292,094
Ensembl chr 1:164,225,934...164,292,093
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
increases phosphorylation |
EXP |
butylbenzyl phthalate results in increased phosphorylation of MAPK1 protein |
CTD |
PMID:31319113 |
|
NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
increases phosphorylation |
EXP |
butylbenzyl phthalate results in increased phosphorylation of MAPK3 protein |
CTD |
PMID:31319113 |
|
NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
|
|
G |
Mapt |
microtubule-associated protein tau |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of MAPT mRNA |
CTD |
PMID:31199487 |
|
NCBI chr10:92,289,002...92,386,517
Ensembl chr10:92,288,910...92,386,517
|
|
G |
Mir141 |
microRNA 141 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in increased expression of MIR141 |
CTD |
PMID:31199487 |
|
NCBI chr 4:157,236,346...157,236,439
Ensembl chr 4:157,236,346...157,236,439
|
|
G |
Mir15b |
microRNA 15b |
decreases expression |
ISO |
butylbenzyl phthalate results in decreased expression of MIR15B mRNA |
CTD |
PMID:31629899 |
|
NCBI chr 2:165,605,923...165,606,020
Ensembl chr 2:165,605,923...165,606,020
|
|
G |
Mir184 |
microRNA 184 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in increased expression of MIR184 |
CTD |
PMID:31199487 |
|
NCBI chr 8:97,175,657...97,175,733
Ensembl chr 8:97,175,657...97,175,733
|
|
G |
Mir19a |
microRNA 19a |
multiple interactions increases expression |
ISO |
MIR19A mRNA affects the reaction [butylbenzyl phthalate results in decreased expression of CDKN1A protein]; MIR19A mRNA affects the reaction [butylbenzyl phthalate results in decreased expression of PTEN protein]; MIR19A mRNA affects the reaction [butylbenzyl phthalate results in increased expression of CCND1 protein]; MIR19A mRNA affects the reaction [butylbenzyl phthalate results in increased expression of PCNA protein] butylbenzyl phthalate results in increased expression of MIR19A mRNA |
CTD |
PMID:29864457 |
|
NCBI chr15:100,180,162...100,180,243
Ensembl chr15:100,180,162...100,180,243
|
|
G |
Mir19b1 |
microRNA 19b-1 |
multiple interactions increases expression |
ISO |
MIR19B1 mRNA affects the reaction [butylbenzyl phthalate results in decreased expression of CDKN1A protein]; MIR19B1 mRNA affects the reaction [butylbenzyl phthalate results in decreased expression of PTEN protein]; MIR19B1 mRNA affects the reaction [butylbenzyl phthalate results in increased expression of CCND1 protein]; MIR19B1 mRNA affects the reaction [butylbenzyl phthalate results in increased expression of PCNA protein] butylbenzyl phthalate results in increased expression of MIR19B1 mRNA |
CTD |
PMID:29864457 |
|
NCBI chr15:100,180,464...100,180,550
Ensembl chr15:100,180,464...100,180,550
|
|
G |
Mir34a |
microRNA 34a |
multiple interactions decreases expression |
ISO |
MIR34A mRNA inhibits the reaction [butylbenzyl phthalate results in decreased expression of CDKN1A protein]; MIR34A mRNA inhibits the reaction [butylbenzyl phthalate results in increased expression of CCND1 protein]; MIR34A mRNA inhibits the reaction [butylbenzyl phthalate results in increased expression of MYC protein]; MIR34A mRNA inhibits the reaction [butylbenzyl phthalate results in increased expression of PCNA protein] butylbenzyl phthalate results in decreased expression of MIR34A mRNA |
CTD |
PMID:30243731 |
|
NCBI chr 5:167,092,491...167,092,592
Ensembl chr 5:167,092,491...167,092,592
|
|
G |
Mllt11 |
MLLT11, transcription factor 7 cofactor |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of MLLT11 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 2:196,392,936...196,402,106
Ensembl chr 2:196,392,938...196,402,106
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
multiple interactions increases expression |
ISO |
ZEB1 protein affects the reaction [butylbenzyl phthalate results in increased expression of MMP2 protein] |
CTD |
PMID:31212022 |
|
NCBI chr19:15,542,771...15,570,589
Ensembl chr19:15,542,765...15,570,611
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
increases expression |
ISO |
butylbenzyl phthalate results in increased expression of MMP9 protein |
CTD |
PMID:31212022 |
|
NCBI chr 3:161,413,410...161,421,473
Ensembl chr 3:161,413,298...161,421,520
|
|
G |
Msh2 |
mutS homolog 2 |
decreases expression |
EXP |
butylbenzyl phthalate results in decreased expression of MSH2 mRNA |
CTD |
PMID:26472102 |
|
NCBI chr 6:11,215,951...11,274,916
Ensembl chr 6:11,215,963...11,274,932
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
multiple interactions increases expression |
ISO |
MIR34A mRNA inhibits the reaction [butylbenzyl phthalate results in increased expression of MYC protein] butylbenzyl phthalate results in increased expression of MYC mRNA; butylbenzyl phthalate results in increased expression of MYC protein |
CTD |
PMID:30243731 |
|
NCBI chr 7:102,586,313...102,591,240
Ensembl chr 7:102,586,313...102,591,240
|
|
G |
Myocd |
myocardin |
decreases expression |
EXP |
butylbenzyl phthalate results in decreased expression of MYOCD mRNA |
CTD |
PMID:26472102 |
|
NCBI chr10:51,682,053...51,781,458
Ensembl chr10:51,683,540...51,778,986
|
|
G |
Ncs1 |
neuronal calcium sensor 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of NCS1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 3:10,556,250...10,602,672
Ensembl chr 3:10,553,589...10,602,672
|
|
G |
Ndrg4 |
NDRG family member 4 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of NDRG4 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr19:9,766,439...9,802,396
Ensembl chr19:9,766,439...9,801,942
|
|
G |
Nefh |
neurofilament heavy |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of NEFH mRNA |
CTD |
PMID:31199487 |
|
NCBI chr14:85,181,572...85,191,557
Ensembl chr14:85,181,572...85,191,557
|
|
G |
Nefl |
neurofilament light |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of NEFL mRNA |
CTD |
PMID:31199487 |
|
NCBI chr15:44,799,378...44,803,251
Ensembl chr15:44,799,334...44,804,574
|
|
G |
Nell1 |
neural EGFL like 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of NELL1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 1:105,348,577...106,218,970
Ensembl chr 1:105,349,069...106,218,958
|
|
G |
Nfe2l2 |
nuclear factor, erythroid 2-like 2 |
decreases expression |
ISO |
butylbenzyl phthalate results in decreased expression of NFE2L2 mRNA |
CTD |
PMID:27923775 |
|
NCBI chr 3:62,497,568...62,525,146
Ensembl chr 3:62,497,571...62,524,996
|
|
G |
Nfil3 |
nuclear factor, interleukin 3 regulated |
increases expression |
EXP |
butylbenzyl phthalate results in increased expression of NFIL3 mRNA |
CTD |
PMID:15728792 |
|
NCBI chr17:12,261,102...12,276,316
Ensembl chr17:12,261,102...12,276,315
|
|
G |
Ngfr |
nerve growth factor receptor |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of NGFR mRNA |
CTD |
PMID:31199487 |
|
NCBI chr10:83,389,828...83,408,061
Ensembl chr10:83,389,847...83,408,061
|
|
G |
Nr0b1 |
nuclear receptor subfamily 0, group B, member 1 |
decreases expression |
EXP |
butylbenzyl phthalate results in decreased expression of NR0B1 mRNA |
CTD |
PMID:15728792 |
|
NCBI chr X:54,734,385...54,738,513
Ensembl chr X:54,734,385...54,738,513
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
increases activity |
ISO |
butylbenzyl phthalate results in increased activity of NR1I2 protein |
CTD |
PMID:27551952 |
|
NCBI chr11:65,022,100...65,058,546
Ensembl chr11:65,022,100...65,058,545
|
|
G |
Nr1i3 |
nuclear receptor subfamily 1, group I, member 3 |
affects binding increases activity |
ISO |
butylbenzyl phthalate binds to NR1I3 protein butylbenzyl phthalate results in increased activity of NR1I3 protein; butylbenzyl phthalate results in increased activity of NR1I3 protein alternative form |
CTD |
PMID:25938866 PMID:27551952 PMID:28927721 |
|
NCBI chr13:89,585,072...89,591,278
Ensembl chr13:89,586,283...89,591,277
|
|
G |
Nr4a3 |
nuclear receptor subfamily 4, group A, member 3 |
decreases expression |
EXP |
butylbenzyl phthalate results in decreased expression of NR4A3 mRNA |
CTD |
PMID:19560483 |
|
NCBI chr 5:63,781,801...63,822,890
Ensembl chr 5:63,781,801...63,821,637
|
|
G |
Nrf1 |
nuclear respiratory factor 1 |
decreases expression |
ISO |
butylbenzyl phthalate results in decreased expression of NRF1 mRNA |
CTD |
PMID:26520405 PMID:27923775 |
|
NCBI chr 4:57,335,732...57,445,317
Ensembl chr 4:57,378,069...57,445,341
|
|
G |
Nrxn2 |
neurexin 2 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of NRXN2 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 1:221,792,191...221,908,047
Ensembl chr 1:221,792,221...221,908,049
|
|
G |
Nsdhl |
NAD(P) dependent steroid dehydrogenase-like |
decreases expression |
EXP |
butylbenzyl phthalate results in decreased expression of NSDHL mRNA |
CTD |
PMID:19560483 |
|
NCBI chr X:152,933,118...152,964,399
Ensembl chr X:152,933,069...152,964,390
|
|
G |
Nsg1 |
neuronal vesicle trafficking associated 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of NSG1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr14:77,380,264...77,402,007
Ensembl chr14:77,380,262...77,401,996
|
|
G |
Nsg2 |
neuronal vesicle trafficking associated 2 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of NSG2 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr10:15,867,885...15,928,169
Ensembl chr10:15,867,887...15,928,169
|
|
G |
Olfm1 |
olfactomedin 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of OLFM1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 3:6,761,031...6,798,739
Ensembl chr 3:6,773,813...6,798,737
|
|
G |
Pcna |
proliferating cell nuclear antigen |
multiple interactions increases expression |
ISO |
MIR19A mRNA affects the reaction [butylbenzyl phthalate results in increased expression of PCNA protein]; MIR19B1 mRNA affects the reaction [butylbenzyl phthalate results in increased expression of PCNA protein]; MIR34A mRNA inhibits the reaction [butylbenzyl phthalate results in increased expression of PCNA protein] butylbenzyl phthalate results in increased expression of PCNA mRNA; butylbenzyl phthalate results in increased expression of PCNA protein |
CTD |
PMID:29864457 PMID:30243731 |
|
NCBI chr 3:124,880,698...124,884,570
Ensembl chr 3:124,880,698...124,884,570
|
|
G |
Pcp4 |
Purkinje cell protein 4 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of PCP4 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr11:36,851,035...36,912,272
Ensembl chr11:36,851,038...36,912,229
|
|
G |
Pdk4 |
pyruvate dehydrogenase kinase 4 |
increases expression multiple interactions |
ISO |
butylbenzyl phthalate results in increased expression of PDK4 protein butylbenzyl phthalate results in increased expression of and results in increased stability of PDK4 mRNA |
CTD |
PMID:31629899 |
|
NCBI chr 4:30,546,772...30,556,774
Ensembl chr 4:30,546,664...30,556,814
|
|
G |
Pdp2 |
pyruvate dehydrogenase phosphatase catalytic subunit 2 |
increases expression |
ISO |
butylbenzyl phthalate results in increased expression of PDP2 mRNA |
CTD |
PMID:31629899 |
|
NCBI chr19:597,427...601,556
Ensembl chr19:597,427...601,469
|
|
G |
Pgr |
progesterone receptor |
increases expression |
EXP |
butylbenzyl phthalate results in increased expression of PGR mRNA |
CTD |
PMID:11474214 |
|
NCBI chr 8:7,128,656...7,187,796
Ensembl chr 8:7,128,656...7,187,796
|
|
G |
Plin1 |
perilipin 1 |
multiple interactions |
ISO |
[1-Methyl-3-isobutylxanthine co-treated with butylbenzyl phthalate co-treated with INS protein] results in increased expression of PLIN1 protein |
CTD |
PMID:26820058 |
|
NCBI chr 1:141,458,907...141,470,927
Ensembl chr 1:141,458,181...141,471,010
|
|
G |
Plppr3 |
phospholipid phosphatase related 3 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of PLPPR3 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 7:12,652,555...12,663,825
Ensembl chr 7:12,652,415...12,663,819
|
|
G |
Pls1 |
plastin 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of PLS1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 8:103,557,361...103,659,625
Ensembl chr 8:103,557,364...103,608,913
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
affects binding multiple interactions |
ISO |
butylbenzyl phthalate binds to PPARA protein [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of PPARA mRNA |
CTD |
PMID:23843199 PMID:28013214 |
|
NCBI chr 7:126,618,872...126,687,282
Ensembl chr 7:126,619,196...126,681,752
|
|
G |
Ppard |
peroxisome proliferator-activated receptor delta |
affects binding |
ISO |
butylbenzyl phthalate binds to PPARB protein |
CTD |
PMID:23843199 |
|
NCBI chr20:7,818,289...7,883,482
Ensembl chr20:7,818,289...7,885,333
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
affects binding increases activity increases expression multiple interactions |
ISO |
butylbenzyl phthalate binds to PPARG protein butylbenzyl phthalate results in increased activity of PPARG protein butylbenzyl phthalate results in increased expression of PPARG mRNA [1-Methyl-3-isobutylxanthine co-treated with butylbenzyl phthalate co-treated with INS protein] results in increased expression of PPARG mRNA; [1-Methyl-3-isobutylxanthine co-treated with butylbenzyl phthalate co-treated with INS protein] results in increased expression of PPARG protein; butylbenzyl phthalate promotes the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of PPARG mRNA]; Curcumin inhibits the reaction [butylbenzyl phthalate promotes the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of PPARG mRNA]]; PPARG protein promotes the reaction [butylbenzyl phthalate binds to and results in increased activity of PPARG protein] butylbenzyl phthalate binds to and results in increased activity of PPARG protein; butylbenzyl phthalate inhibits the reaction [GW 1929 binds to PPARG protein] |
CTD |
PMID:23843199 PMID:24155963 PMID:26172262 PMID:26820058 PMID:27923775 PMID:28595985 PMID:31016361 PMID:32407875 |
|
NCBI chr 4:147,274,055...147,399,383
Ensembl chr 4:147,274,107...147,399,380
|
|
G |
Ppargc1a |
PPARG coactivator 1 alpha |
decreases expression affects expression |
ISO |
butylbenzyl phthalate results in decreased expression of PPARGC1A mRNA butylbenzyl phthalate affects the expression of PPARGC1A mRNA |
CTD |
PMID:26520405 PMID:27923775 |
|
NCBI chr14:63,095,291...63,190,688
Ensembl chr14:63,095,720...63,187,009
|
|
G |
Ppp2r2b |
protein phosphatase 2, regulatory subunit B, beta |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of PPP2R2B mRNA |
CTD |
PMID:31199487 |
|
NCBI chr18:36,985,709...37,421,383
Ensembl chr18:36,985,714...37,245,809
|
|
G |
Prima1 |
proline rich membrane anchor 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of PRIMA1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 6:127,075,954...127,127,985
Ensembl chr 6:127,075,954...127,127,413
|
|
G |
Prph |
peripherin |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of PRPH mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 7:140,742,406...140,746,197
Ensembl chr 7:140,742,418...140,746,197
|
|
G |
Pten |
phosphatase and tensin homolog |
decreases expression multiple interactions |
ISO |
butylbenzyl phthalate results in decreased expression of PTEN mRNA; butylbenzyl phthalate results in decreased expression of PTEN protein MIR19A mRNA affects the reaction [butylbenzyl phthalate results in decreased expression of PTEN protein]; MIR19B1 mRNA affects the reaction [butylbenzyl phthalate results in decreased expression of PTEN protein] |
CTD |
PMID:29864457 |
|
NCBI chr 1:251,421,814...251,487,634
Ensembl chr 1:251,421,596...251,487,832
|
|
G |
Ptges |
prostaglandin E synthase |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of PTGES mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 3:9,727,408...9,738,752
Ensembl chr 3:9,727,408...9,738,752
|
|
G |
Ptgr1 |
prostaglandin reductase 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of PTGR1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 5:76,110,746...76,129,361
Ensembl chr 5:76,110,738...76,129,441
|
|
G |
Ptprn |
protein tyrosine phosphatase, receptor type, N |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of PTPRN mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 9:82,446,626...82,462,314
Ensembl chr 9:82,446,633...82,461,903
|
|
G |
Qsox1 |
quiescin sulfhydryl oxidase 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of QSOX1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr13:73,423,396...73,460,890
Ensembl chr13:73,423,397...73,460,935
|
|
G |
Rab3b |
RAB3B, member RAS oncogene family |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of RAB3B mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 5:128,501,789...128,568,170
Ensembl chr 5:128,501,847...128,568,188
|
|
G |
Rab6b |
RAB6B, member RAS oncogene family |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of RAB6B mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 8:111,600,375...111,668,817
Ensembl chr 8:111,600,532...111,668,808
|
|
G |
Rassf4 |
Ras association domain family member 4 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of RASSF4 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 4:148,769,092...148,804,295
Ensembl chr 4:148,769,096...148,803,988
|
|
G |
Resp18 |
regulated endocrine-specific protein 18 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of RESP18 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 9:82,470,794...82,477,136
Ensembl chr 9:82,470,759...82,477,181
|
|
G |
Rnf183 |
ring finger protein 183 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in increased expression of RNF183 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 5:78,283,722...78,292,729
Ensembl chr 5:78,284,879...78,285,451
|
|
G |
Rtn1 |
reticulon 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of RTN1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 6:94,951,016...95,177,477
Ensembl chr 6:94,951,020...95,061,174
|
|
G |
Rtn4r |
reticulon 4 receptor |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of RTN4R mRNA |
CTD |
PMID:31199487 |
|
NCBI chr11:86,992,665...87,017,091
Ensembl chr11:86,992,399...87,017,115
|
|
G |
Rxra |
retinoid X receptor alpha |
affects binding |
ISO |
butylbenzyl phthalate binds to RXRA protein |
CTD |
PMID:23843199 |
|
NCBI chr 3:6,272,560...6,295,354
Ensembl chr 3:6,211,789...6,295,908
|
|
G |
Rxrb |
retinoid X receptor beta |
affects binding |
ISO |
butylbenzyl phthalate binds to RXRB protein |
CTD |
PMID:23843199 |
|
NCBI chr20:3,822,673...3,829,138
Ensembl chr20:3,823,042...3,829,140
|
|
G |
Rxrg |
retinoid X receptor gamma |
affects binding |
ISO |
butylbenzyl phthalate binds to RXRG protein |
CTD |
PMID:23843199 |
|
NCBI chr13:85,818,473...85,868,555
Ensembl chr13:85,818,427...85,868,552
|
|
G |
Scarb1 |
scavenger receptor class B, member 1 |
decreases expression |
EXP |
butylbenzyl phthalate results in decreased expression of SCARB1 mRNA; butylbenzyl phthalate results in decreased expression of SCARB1 protein |
CTD |
PMID:26472102 PMID:31319113 |
|
NCBI chr12:36,694,952...36,761,445
Ensembl chr12:36,694,960...36,761,455
|
|
G |
Scg3 |
secretogranin III |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of SCG3 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 8:82,582,352...82,641,536
Ensembl chr 8:82,582,352...82,641,536
|
|
G |
Scn3b |
sodium voltage-gated channel beta subunit 3 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of SCN3B mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 8:44,136,413...44,159,011
Ensembl chr 8:44,136,496...44,159,010
|
|
G |
Scrn1 |
secernin 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of SCRN1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 4:84,678,978...84,740,701
Ensembl chr 4:84,678,975...84,740,909
|
|
G |
Sh3gl3 |
SH3 domain containing GRB2 like 3, endophilin A3 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of SH3GL3 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 1:144,069,641...144,200,402
Ensembl chr 1:144,069,638...144,200,397
|
|
G |
Sh3tc2 |
SH3 domain and tetratricopeptide repeats 2 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of SH3TC2 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr18:57,286,266...57,403,926
Ensembl chr18:57,286,322...57,347,577
|
|
G |
Shbg |
sex hormone binding globulin |
affects binding |
ISO |
butylbenzyl phthalate binds to SHBG protein |
CTD |
PMID:25349334 |
|
NCBI chr10:56,219,861...56,237,354
Ensembl chr10:56,219,858...56,223,245
|
|
G |
Shc2 |
SHC adaptor protein 2 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of SHC2 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 7:12,948,952...12,971,174
Ensembl chr 7:12,948,952...12,971,174
|
|
G |
Sirt1 |
sirtuin 1 |
decreases expression |
ISO |
butylbenzyl phthalate results in decreased expression of SIRT1 mRNA; butylbenzyl phthalate results in decreased expression of SIRT1 protein |
CTD |
PMID:26520405 PMID:27923775 |
|
NCBI chr20:26,831,971...26,851,587
Ensembl chr20:26,833,357...26,852,199
|
|
G |
Sirt3 |
sirtuin 3 |
decreases expression |
ISO |
butylbenzyl phthalate results in decreased expression of SIRT3 mRNA; butylbenzyl phthalate results in decreased expression of SIRT3 protein |
CTD |
PMID:26520405 PMID:27923775 |
|
NCBI chr 1:213,613,502...213,636,061
Ensembl chr 1:213,613,513...213,635,546
|
|
G |
Sirt7 |
sirtuin 7 |
decreases expression affects expression |
ISO |
butylbenzyl phthalate results in decreased expression of SIRT7 mRNA butylbenzyl phthalate affects the expression of SIRT7 mRNA |
CTD |
PMID:27923775 PMID:31016965 |
|
NCBI chr10:109,796,046...109,802,821
Ensembl chr10:109,796,020...109,802,739
|
|
G |
Slc13a2 |
solute carrier family 13 member 2 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of SLC13A2 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr10:65,664,665...65,692,046
Ensembl chr10:65,664,667...65,692,023
|
|
G |
Slc29a4 |
solute carrier family 29 member 4 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of SLC29A4 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr12:13,914,114...13,924,511
Ensembl chr12:13,914,114...13,924,531
|
|
G |
Slc5a5 |
solute carrier family 5 member 5 |
increases expression |
ISO EXP |
butylbenzyl phthalate results in increased expression of SLC5A5 mRNA |
CTD |
PMID:16257484 |
|
NCBI chr16:20,297,414...20,307,401
Ensembl chr16:20,297,414...20,307,400
|
|
G |
Slc5a7 |
solute carrier family 5 member 7 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of SLC5A7 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 9:5,294,377...5,330,822
Ensembl chr 9:5,294,381...5,330,815
|
|
G |
Smim24 |
small integral membrane protein 24 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of SMIM24 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 7:11,182,975...11,187,222
Ensembl chr 7:11,183,570...11,186,130
|
|
G |
Snhg11 |
small nucleolar RNA host gene 11 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of SNHG11 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 3:154,862,717...154,870,691
Ensembl chr 3:154,863,072...154,869,460
|
|
G |
Sod1 |
superoxide dismutase 1 |
multiple interactions |
ISO |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of SOD1 mRNA |
CTD |
PMID:28013214 |
|
NCBI chr11:30,363,282...30,368,858
Ensembl chr11:30,363,280...30,368,862
|
|
G |
Sohlh2 |
spermatogenesis and oogenesis specific basic helix-loop-helix 2 |
increases expression decreases expression multiple interactions |
EXP |
butylbenzyl phthalate results in increased expression of SOHLH2 mRNA butylbenzyl phthalate results in decreased expression of SOHLH2 protein 4-vinyl-1-cyclohexene dioxide inhibits the reaction [butylbenzyl phthalate results in increased expression of SOHLH2 mRNA]; [4-vinyl-1-cyclohexene dioxide co-treated with butylbenzyl phthalate] results in decreased expression of SOHLH2 protein |
CTD |
PMID:29969652 |
|
NCBI chr 2:144,591,755...144,614,065
Ensembl chr 2:144,591,755...144,614,064
|
|
G |
Sox9 |
SRY-box transcription factor 9 |
decreases expression increases expression |
EXP |
butylbenzyl phthalate results in decreased expression of SOX9 mRNA butylbenzyl phthalate results in increased expression of SOX9 mRNA; butylbenzyl phthalate results in increased expression of SOX9 protein |
CTD |
PMID:26472102 PMID:31319113 |
|
NCBI chr10:101,288,528...101,294,030
Ensembl chr10:101,288,489...101,293,379
|
|
G |
Sp1 |
Sp1 transcription factor |
decreases expression multiple interactions |
ISO |
butylbenzyl phthalate results in decreased expression of SP1 mRNA [Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with 4-nonylphenol co-treated with 4-tert-octylphenol] results in decreased expression of SP1 mRNA |
CTD |
PMID:29029336 |
|
NCBI chr 7:144,014,173...144,044,635
Ensembl chr 7:144,014,173...144,044,629
|
|
G |
Src |
SRC proto-oncogene, non-receptor tyrosine kinase |
multiple interactions increases phosphorylation |
ISO |
fulvestrant inhibits the reaction [butylbenzyl phthalate results in increased phosphorylation of SRC protein] |
CTD |
PMID:22552774 |
|
NCBI chr 3:153,547,807...153,595,643
Ensembl chr 3:153,580,861...153,595,642
|
|
G |
Srd5a1 |
steroid 5 alpha-reductase 1 |
decreases expression |
EXP |
butylbenzyl phthalate results in decreased expression of SRD5A1 mRNA |
CTD |
PMID:19560483 |
|
NCBI chr 1:36,320,504...36,354,694
Ensembl chr 1:36,320,461...36,354,756
|
|
G |
Star |
steroidogenic acute regulatory protein |
decreases expression multiple interactions increases expression |
EXP ISO |
butylbenzyl phthalate results in decreased expression of STAR mRNA; butylbenzyl phthalate results in decreased expression of STAR protein [diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of STAR mRNA; [Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with 4-nonylphenol co-treated with 4-tert-octylphenol] results in increased expression of STAR mRNA; [Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diethyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate co-treated with diisononyl phthalate] results in decreased expression of STAR mRNA butylbenzyl phthalate results in increased expression of STAR mRNA |
CTD |
PMID:19560483 PMID:26472102 PMID:28013214 PMID:29029336 PMID:30802670 PMID:31319113 |
|
NCBI chr16:71,036,204...71,040,847
Ensembl chr16:71,036,204...71,040,847
|
|
G |
Stk32c |
serine/threonine kinase 32C |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of STK32C mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 1:211,440,335...211,520,699
Ensembl chr 1:211,440,335...211,520,699
|
|
G |
Stmn4 |
stathmin 4 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of STMN4 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr15:43,007,901...43,025,852
Ensembl chr15:43,007,908...43,025,852
|
|
G |
Syt11 |
synaptotagmin 11 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of SYT11 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 2:188,112,301...188,138,180
Ensembl chr 2:188,112,286...188,138,177
|
|
G |
Syt5 |
synaptotagmin 5 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of SYT5 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 1:72,859,806...72,867,934
Ensembl chr 1:72,860,218...72,867,930
|
|
G |
Tbx2 |
T-box transcription factor 2 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of TBX2 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr10:73,278,932...73,290,764
Ensembl chr10:73,279,119...73,289,921
|
|
G |
Tcf21 |
transcription factor 21 |
increases expression decreases expression |
EXP |
butylbenzyl phthalate results in increased expression of TCF21 mRNA butylbenzyl phthalate results in decreased expression of TCF21 mRNA |
CTD |
PMID:26472102 |
|
NCBI chr 1:23,906,717...23,909,576
Ensembl chr 1:23,906,717...23,909,566
|
|
G |
Tcf23 |
transcription factor 23 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of TCF23 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 6:26,763,159...26,772,074
Ensembl chr 6:26,762,761...26,771,164
|
|
G |
Tcf4 |
transcription factor 4 |
multiple interactions |
ISO |
butylbenzyl phthalate promotes the reaction [[TCF4 protein binds to LEF1 protein] which binds to VIM protein]; HDAC6 mutant form inhibits the reaction [butylbenzyl phthalate promotes the reaction [[TCF4 protein binds to LEF1 protein] which binds to VIM protein]]; trichostatin A inhibits the reaction [butylbenzyl phthalate promotes the reaction [[TCF4 protein binds to LEF1 protein] which binds to VIM protein]] |
CTD |
PMID:22552774 |
|
NCBI chr18:65,285,320...65,507,983
Ensembl chr18:65,155,685...65,507,977
|
|
G |
Tcte1 |
t-complex-associated testis expressed 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of TCTE1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 9:17,847,866...17,867,276
Ensembl chr 9:17,846,364...17,866,927
|
|
G |
Tfam |
transcription factor A, mitochondrial |
decreases expression |
ISO |
butylbenzyl phthalate results in decreased expression of TFAM mRNA |
CTD |
PMID:27923775 |
|
NCBI chr20:18,594,057...18,606,106
Ensembl chr20:18,594,037...18,606,151
|
|
G |
Tfap2a |
transcription factor AP-2 alpha |
affects localization multiple interactions |
ISO |
butylbenzyl phthalate affects the localization of TFAP2A protein [butylbenzyl phthalate promotes the reaction [TFAP2A protein binds to HDAC6 promoter]] which results in increased expression of HDAC6 mRNA; butylbenzyl phthalate promotes the reaction [TFAP2A protein binds to HDAC6 promoter]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [butylbenzyl phthalate affects the localization of TFAP2A protein]; RTKI cpd inhibits the reaction [butylbenzyl phthalate affects the localization of TFAP2A protein]; TFAP2A mutant form inhibits the reaction [butylbenzyl phthalate results in increased expression of HDAC6 protein] |
CTD |
PMID:22552774 |
|
NCBI chr17:24,653,342...24,670,457
Ensembl chr17:24,654,902...24,670,457
|
|
G |
Thy1 |
Thy-1 cell surface antigen |
increases expression |
ISO |
butylbenzyl phthalate results in increased expression of THY1 protein |
CTD |
PMID:22552774 |
|
NCBI chr 8:48,382,121...48,387,271
Ensembl chr 8:48,382,121...48,386,935
|
|
G |
Tmeff2 |
transmembrane protein with EGF-like and two follistatin-like domains 2 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of TMEFF2 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 9:55,379,130...55,673,704
Ensembl chr 9:55,384,100...55,673,829
|
|
G |
Tmem130 |
transmembrane protein 130 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of TMEM130 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr12:11,814,071...11,840,100
Ensembl chr12:11,814,071...11,840,100
|
|
G |
Tmem35a |
transmembrane protein 35A |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of TMEM35A mRNA |
CTD |
PMID:31199487 |
|
NCBI chr X:105,134,498...105,145,346
Ensembl chr X:105,134,498...105,145,345
|
|
G |
Tmem63c |
transmembrane protein 63c |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of TMEM63C mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 6:111,044,099...111,120,659
Ensembl chr 6:111,049,559...111,120,799
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
butylbenzyl phthalate inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; butylbenzyl phthalate promotes the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of TNF mRNA]; Curcumin inhibits the reaction [butylbenzyl phthalate promotes the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of TNF mRNA]] |
CTD |
PMID:15256756 PMID:28595985 |
|
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
|
|
G |
Tnfrsf11b |
TNF receptor superfamily member 11B |
multiple interactions |
ISO |
butylbenzyl phthalate promotes the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in decreased secretion of TNFRSF11B protein] |
CTD |
PMID:31016361 |
|
NCBI chr 7:93,798,580...93,826,586
Ensembl chr 7:93,798,545...93,826,665
|
|
G |
Trpc6 |
transient receptor potential cation channel, subfamily C, member 6 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of TRPC6 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 8:6,811,543...6,917,534
Ensembl chr 8:6,811,543...6,917,535
|
|
G |
Ttyh1 |
tweety family member 1 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of TTYH1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 1:73,734,614...73,753,157
Ensembl chr 1:73,734,624...73,753,128
|
|
G |
Tubb2b |
tubulin, beta 2B class IIb |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of TUBB2B mRNA |
CTD |
PMID:31199487 |
|
NCBI chr17:31,441,640...31,444,687
Ensembl chr17:31,441,630...31,482,759
|
|
G |
Tubb3 |
tubulin, beta 3 class III |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of TUBB3 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr19:56,220,759...56,229,813
Ensembl chr19:56,220,755...56,229,813
|
|
G |
Tubb4a |
tubulin, beta 4A class IVa |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of TUBB4A mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 9:9,961,020...9,968,420
Ensembl chr 9:9,961,021...9,968,486
|
|
G |
Ubash3b |
ubiquitin associated and SH3 domain containing, B |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of UBASH3B mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 8:45,224,053...45,375,450
Ensembl chr 8:45,223,992...45,375,435
|
|
G |
Ubxn11 |
UBX domain protein 11 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of UBXN11 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 5:152,332,993...152,356,647
Ensembl chr 5:152,333,043...152,356,890
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions decreases secretion increases secretion |
ISO |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [butylbenzyl phthalate results in increased secretion of VEGFA protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [butylbenzyl phthalate results in increased secretion of VEGFA protein]; butylbenzyl phthalate promotes the reaction [Oxygen deficiency results in increased secretion of VEGFA protein]; SB 203580 inhibits the reaction [butylbenzyl phthalate results in increased secretion of VEGFA protein]; Wortmannin inhibits the reaction [butylbenzyl phthalate results in increased secretion of VEGFA protein] butylbenzyl phthalate results in decreased secretion of VEGFA protein |
CTD |
PMID:18252963 PMID:25016925 PMID:30851587 |
|
NCBI chr 9:17,340,341...17,355,681
Ensembl chr 9:17,340,341...17,355,681
|
|
G |
Vim |
vimentin |
multiple interactions increases expression |
ISO |
butylbenzyl phthalate promotes the reaction [[TCF4 protein binds to LEF1 protein] which binds to VIM protein]; HDAC6 mutant form inhibits the reaction [butylbenzyl phthalate promotes the reaction [[TCF4 protein binds to LEF1 protein] which binds to VIM protein]]; HDAC6 mutant form inhibits the reaction [butylbenzyl phthalate results in increased expression of VIM protein]; trichostatin A inhibits the reaction [butylbenzyl phthalate promotes the reaction [[TCF4 protein binds to LEF1 protein] which binds to VIM protein]] |
CTD |
PMID:22552774 PMID:31212022 |
|
NCBI chr17:80,882,715...80,891,200
Ensembl chr17:80,882,666...80,891,212
|
|
G |
Wnt6 |
Wnt family member 6 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of WNT6 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 9:82,033,543...82,047,172
Ensembl chr 9:82,033,543...82,047,166
|
|
G |
Wnt9b |
Wnt family member 9B |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of WNT9B mRNA |
CTD |
PMID:31199487 |
|
NCBI chr10:91,785,892...91,808,061
Ensembl chr10:91,785,893...91,807,937
|
|
G |
Wt1 |
WT1 transcription factor |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of WT1 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 3:95,133,221...95,180,574
Ensembl chr 3:95,133,713...95,180,564
|
|
G |
Zcchc12 |
zinc finger CCHC-type containing 12 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of ZCCHC12 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr X:122,808,581...122,811,790
Ensembl chr X:122,808,605...122,811,789
|
|
G |
Zeb1 |
zinc finger E-box binding homeobox 1 |
multiple interactions increases expression increases stability |
ISO |
butylbenzyl phthalate results in increased expression of and results in increased stability of ZEB1 mRNA; MIR655 mRNA inhibits the reaction [butylbenzyl phthalate results in increased expression of ZEB1 mRNA]; ZEB1 protein affects the reaction [butylbenzyl phthalate results in increased expression of MMP2 protein] butylbenzyl phthalate results in increased expression of ZEB1 protein ATM protein affects the reaction [butylbenzyl phthalate results in increased expression of ZEB1 protein]; butylbenzyl phthalate results in increased expression of and affects the localization of ZEB1 protein; butylbenzyl phthalate results in increased expression of and results in increased stability of ZEB1 mRNA; MIR655 mRNA inhibits the reaction [butylbenzyl phthalate results in increased expression of ZEB1 protein]; ZEB1 protein affects the reaction [butylbenzyl phthalate results in increased expression of MMP2 protein] butylbenzyl phthalate results in increased stability of ZEB1 protein |
CTD |
PMID:31212022 |
|
NCBI chr17:54,656,627...54,714,920
Ensembl chr17:54,658,463...54,714,914
|
|
G |
Zfat |
zinc finger and AT hook domain containing |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in increased expression of ZFAT mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 7:109,037,777...109,207,511
Ensembl chr 7:109,037,845...109,205,354
|
|
G |
Zp2 |
zona pellucida glycoprotein 2 |
multiple interactions |
EXP |
[diethyl phthalate co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with diisononyl phthalate co-treated with diisobutyl phthalate co-treated with butylbenzyl phthalate] results in decreased expression of ZP2 mRNA |
CTD |
PMID:31199487 |
|
NCBI chr 1:189,899,906...189,911,650
Ensembl chr 1:189,899,892...189,911,650
|
|
|
G |
Agt |
angiotensinogen |
multiple interactions |
ISO |
CGP 42112A inhibits the reaction [[AGT protein co-treated with Rotenone] results in increased expression of NOX1 mRNA]; CGP 42112A inhibits the reaction [[AGT protein co-treated with Rotenone] results in increased expression of NOX1 protein]; CGP 42112A inhibits the reaction [[AGT protein co-treated with Rotenone] results in increased expression of NOX2 mRNA]; CGP 42112A inhibits the reaction [[AGT protein co-treated with Rotenone] results in increased expression of NOX2 protein]; CGP 42112A inhibits the reaction [[AGT protein co-treated with Rotenone] results in increased expression of NOX4 mRNA]; CGP 42112A inhibits the reaction [[AGT protein co-treated with Rotenone] results in increased expression of NOX4 protein]; CGP 42112A inhibits the reaction [AGT protein promotes the reaction [Rotenone results in increased expression of AGTRAP mRNA]]; CGP 42112A inhibits the reaction [AGT protein promotes the reaction [Rotenone results in increased expression of AGTRAP protein]]; CGP 42112A promotes the reaction [[AGT protein co-treated with Rotenone] results in increased expression of AGTR2 protein]; CGP 42112A promotes the reaction [AGT protein promotes the reaction [Rotenone results in increased expression of AGTR2 mRNA]]; PD 123319 inhibits the reaction [CGP 42112A inhibits the reaction [[AGT protein co-treated with Rotenone] results in increased expression of NOX1 mRNA]]; PD 123319 inhibits the reaction [CGP 42112A inhibits the reaction [[AGT protein co-treated with Rotenone] results in increased expression of NOX1 protein]]; PD 123319 inhibits the reaction [CGP 42112A inhibits the reaction [[AGT protein co-treated with Rotenone] results in increased expression of NOX2 mRNA]]; PD 123319 inhibits the reaction [CGP 42112A inhibits the reaction [[AGT protein co-treated with Rotenone] results in increased expression of NOX2 protein]]; PD 123319 inhibits the reaction [CGP 42112A inhibits the reaction [[AGT protein co-treated with Rotenone] results in increased expression of NOX4 mRNA]]; PD 123319 inhibits the reaction [CGP 42112A inhibits the reaction [AGT protein promotes the reaction [Rotenone results in increased expression of AGTRAP mRNA]]]; PD 123319 inhibits the reaction [CGP 42112A inhibits the reaction [AGT protein promotes the reaction [Rotenone results in increased expression of AGTRAP protein]]]; PD 123319 inhibits the reaction [CGP 42112A promotes the reaction [[AGT protein co-treated with Rotenone] results in increased expression of AGTR2 protein]]; PD 123319 inhibits the reaction [CGP 42112A promotes the reaction [AGT protein promotes the reaction [Rotenone results in increased expression of AGTR2 mRNA]]] |
CTD |
PMID:25446015 |
|
NCBI chr19:57,321,594...57,333,460
Ensembl chr19:57,321,640...57,333,433
|
|
G |
Agtr2 |
angiotensin II receptor, type 2 |
multiple interactions |
ISO EXP |
CGP 42112A promotes the reaction [[AGT protein co-treated with Rotenone] results in increased expression of AGTR2 protein]; CGP 42112A promotes the reaction [AGT protein promotes the reaction [Rotenone results in increased expression of AGTR2 mRNA]]; PD 123319 inhibits the reaction [CGP 42112A promotes the reaction [[AGT protein co-treated with Rotenone] results in increased expression of AGTR2 protein]]; PD 123319 inhibits the reaction [CGP 42112A promotes the reaction [AGT protein promotes the reaction [Rotenone results in increased expression of AGTR2 mRNA]]] [CGP 42112A binds to and results in increased activity of AGTR2 protein] which affects the susceptibility to Phenylephrine; [CGP 42112A binds to and results in increased activity of AGTR2 protein] which results in increased abundance of and results in increased secretion of Triglycerides; [CGP 42112A binds to and results in increased activity of AGTR2 protein] which results in increased abundance of Fatty Acids, Nonesterified; CGP 42112A binds to and results in increased activity of AGTR2 protein |
CTD |
PMID:16003179 PMID:19151255 PMID:25446015 |
|
NCBI chr X:119,389,480...119,393,845
Ensembl chr X:119,390,013...119,393,842
|
|
G |
Agtrap |
angiotensin II receptor-associated protein |
multiple interactions |
ISO |
CGP 42112A inhibits the reaction [AGT protein promotes the reaction [Rotenone results in increased expression of AGTRAP mRNA]]; CGP 42112A inhibits the reaction [AGT protein promotes the reaction [Rotenone results in increased expression of AGTRAP protein]]; PD 123319 inhibits the reaction [CGP 42112A inhibits the reaction [AGT protein promotes the reaction [Rotenone results in increased expression of AGTRAP mRNA]]]; PD 123319 inhibits the reaction [CGP 42112A inhibits the reaction [AGT protein promotes the reaction [Rotenone results in increased expression of AGTRAP protein]]] |
CTD |
PMID:25446015 |
|
NCBI chr 5:164,888,069...164,898,387
Ensembl chr 5:164,886,813...164,898,420
|
|
G |
Cybb |
cytochrome b-245 beta chain |
multiple interactions |
ISO |
CGP 42112A inhibits the reaction [[AGT protein co-treated with Rotenone] results in increased expression of NOX2 mRNA]; CGP 42112A inhibits the reaction [[AGT protein co-treated with Rotenone] results in increased expression of NOX2 protein]; PD 123319 inhibits the reaction [CGP 42112A inhibits the reaction [[AGT protein co-treated with Rotenone] results in increased expression of NOX2 mRNA]]; PD 123319 inhibits the reaction [CGP 42112A inhibits the reaction [[AGT protein co-treated with Rotenone] results in increased expression of NOX2 protein]] |
CTD |
PMID:25446015 |
|
NCBI chr X:14,578,330...14,610,049
Ensembl chr X:14,578,264...14,612,547
|
|
G |
Nox1 |
NADPH oxidase 1 |
multiple interactions |
ISO |
CGP 42112A inhibits the reaction [[AGT protein co-treated with Rotenone] results in increased expression of NOX1 mRNA]; CGP 42112A inhibits the reaction [[AGT protein co-treated with Rotenone] results in increased expression of NOX1 protein]; PD 123319 inhibits the reaction [CGP 42112A inhibits the reaction [[AGT protein co-treated with Rotenone] results in increased expression of NOX1 mRNA]]; PD 123319 inhibits the reaction [CGP 42112A inhibits the reaction [[AGT protein co-treated with Rotenone] results in increased expression of NOX1 protein]] |
CTD |
PMID:25446015 |
|
NCBI chr X:104,909,328...104,932,508
Ensembl chr X:104,909,326...104,932,508
|
|
G |
Nox4 |
NADPH oxidase 4 |
multiple interactions |
ISO |
CGP 42112A inhibits the reaction [[AGT protein co-treated with Rotenone] results in increased expression of NOX4 mRNA]; CGP 42112A inhibits the reaction [[AGT protein co-treated with Rotenone] results in increased expression of NOX4 protein]; PD 123319 inhibits the reaction [CGP 42112A inhibits the reaction [[AGT protein co-treated with Rotenone] results in increased expression of NOX4 mRNA]] |
CTD |
PMID:25446015 |
|
NCBI chr 1:150,796,359...150,976,186
Ensembl chr 1:150,797,084...150,976,194
|
|
G |
Ube2v2 |
ubiquitin conjugating enzyme E2 V2 |
increases expression |
EXP |
CGP 42112A results in increased expression of UBE2V2 mRNA; CGP 42112A results in increased expression of UBE2V2 protein |
CTD |
PMID:17068200 |
|
NCBI chr11:89,557,273...89,591,175
Ensembl chr11:89,557,273...89,591,175
|
|
|
G |
Ache |
acetylcholinesterase |
multiple interactions decreases activity |
ISO |
[crotoxyphos co-treated with Dichlorvos] results in decreased activity of ACHE protein crotoxyphos results in decreased activity of ACHE protein |
CTD |
PMID:4859365 |
|
NCBI chr12:22,472,358...22,477,052
Ensembl chr12:22,472,358...22,478,753
|
|
|
G |
Ahr |
aryl hydrocarbon receptor |
affects expression multiple interactions |
ISO |
mono-benzyl phthalate affects the expression of AHR mRNA [monoethyl phthalate co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono-isobutyl phthalate co-treated with monoisononylphthalate co-treated with mono-benzyl phthalate] affects the expression of AHR mRNA |
CTD |
PMID:28381288 PMID:31884101 |
|
NCBI chr 6:54,963,990...55,001,806
Ensembl chr 6:54,963,990...55,001,464
|
|
G |
Ahrr |
aryl-hydrocarbon receptor repressor |
multiple interactions |
ISO |
[monoethyl phthalate co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono-isobutyl phthalate co-treated with monoisononylphthalate co-treated with mono-benzyl phthalate] affects the expression of AHRR mRNA |
CTD |
PMID:31884101 |
|
NCBI chr 1:31,603,297...31,698,329
Ensembl chr 1:31,603,297...31,698,329
|
|
G |
Aifm1 |
apoptosis inducing factor, mitochondria associated 1 |
multiple interactions |
ISO |
[monoethyl phthalate co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono-isobutyl phthalate co-treated with monoisononylphthalate co-treated with mono-benzyl phthalate] results in increased expression of AIFM1 mRNA |
CTD |
PMID:31884101 |
|
NCBI chr X:135,304,063...135,343,062
Ensembl chr X:135,304,066...135,343,087
|
|
G |
Ar |
androgen receptor |
multiple interactions |
ISO |
mono-benzyl phthalate promotes the reaction [Dihydrotestosterone results in increased activity of AR protein] [monoethyl phthalate co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono-isobutyl phthalate co-treated with monoisononylphthalate co-treated with mono-benzyl phthalate] results in decreased expression of AR mRNA |
CTD |
PMID:28571686 PMID:31884101 |
|
NCBI chr X:67,656,253...67,828,998
Ensembl chr X:67,656,253...67,829,026
|
|
G |
Arnt |
aryl hydrocarbon receptor nuclear translocator |
multiple interactions |
ISO |
[monoethyl phthalate co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono-isobutyl phthalate co-treated with monoisononylphthalate co-treated with mono-benzyl phthalate] affects the expression of ARNT mRNA |
CTD |
PMID:31884101 |
|
NCBI chr 2:196,594,178...196,651,486
Ensembl chr 2:196,594,303...196,651,179
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
ISO |
[monoethyl phthalate co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono-isobutyl phthalate co-treated with monoisononylphthalate co-treated with mono-benzyl phthalate] results in increased expression of BAX mRNA |
CTD |
PMID:31884101 |
|
NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
ISO |
[monoethyl phthalate co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono-isobutyl phthalate co-treated with monoisononylphthalate co-treated with mono-benzyl phthalate] affects the expression of BCL2 mRNA |
CTD |
PMID:31884101 |
|
NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
|
|
G |
Bcl2l10 |
BCL2 like 10 |
multiple interactions |
ISO |
[monoethyl phthalate co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono-isobutyl phthalate co-treated with monoisononylphthalate co-treated with mono-benzyl phthalate] results in decreased expression of BCL2L10 mRNA |
CTD |
PMID:31884101 |
|
NCBI chr 8:82,288,705...82,294,750
Ensembl chr 8:82,288,705...82,294,744
|
|
G |
Bid |
BH3 interacting domain death agonist |
multiple interactions |
ISO |
[monoethyl phthalate co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono-isobutyl phthalate co-treated with monoisononylphthalate co-treated with mono-benzyl phthalate] results in increased expression of BID mRNA |
CTD |
PMID:31884101 |
|
NCBI chr 4:153,439,812...153,465,247
Ensembl chr 4:153,442,218...153,465,203
|
|
G |
Bok |
BCL2 family apoptosis regulator BOK |
multiple interactions |
ISO |
[monoethyl phthalate co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono-isobutyl phthalate co-treated with monoisononylphthalate co-treated with mono-benzyl phthalate] results in decreased expression of BOK mRNA |
CTD |
PMID:31884101 |
|
NCBI chr 9:100,829,593...100,840,498
Ensembl chr 9:100,829,552...100,840,504
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO |
[monoethyl phthalate co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono-isobutyl phthalate co-treated with monoisononylphthalate co-treated with mono-benzyl phthalate] results in decreased expression of CASP3 mRNA |
CTD |
PMID:31884101 |
|
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
|
|
G |
Casp8 |
caspase 8 |
multiple interactions |
ISO |
[monoethyl phthalate co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono-isobutyl phthalate co-treated with monoisononylphthalate co-treated with mono-benzyl phthalate] results in decreased expression of CASP8 mRNA |
CTD |
PMID:31884101 |
|
NCBI chr 9:65,614,142...65,662,624
Ensembl chr 9:65,614,142...65,662,106
|
|
G |
Cat |
catalase |
multiple interactions |
ISO |
[monoethyl phthalate co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono-isobutyl phthalate co-treated with monoisononylphthalate co-treated with mono-benzyl phthalate] results in increased expression of CAT mRNA |
CTD |
PMID:31884101 |
|
NCBI chr 3:93,379,872...93,412,058
Ensembl chr 3:93,379,874...93,412,058
|
|
G |
Ccna2 |
cyclin A2 |
multiple interactions |
ISO |
[monoethyl phthalate co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono-isobutyl phthalate co-treated with monoisononylphthalate co-treated with mono-benzyl phthalate] results in decreased expression of CCNA2 mRNA |
CTD |
PMID:31884101 |
|
NCBI chr 2:123,274,727...123,282,266
Ensembl chr 2:123,275,881...123,282,214
|
|
G |
Ccnb1 |
cyclin B1 |
multiple interactions |
ISO |
[monoethyl phthalate co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono-isobutyl phthalate co-treated with monoisononylphthalate co-treated with mono-benzyl phthalate] results in decreased expression of CCNB1 mRNA |
CTD |
PMID:31884101 |
|
NCBI chr 2:30,782,133...30,791,106
Ensembl chr 2:30,783,915...30,791,221
|
|
G |
Ccnb2 |
cyclin B2 |
multiple interactions |
ISO |
[monoethyl phthalate co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono-isobutyl phthalate co-treated with monoisononylphthalate co-treated with mono-benzyl phthalate] results in decreased expression of CCNB2 mRNA |
CTD |
PMID:31884101 |
|
NCBI chr 8:76,847,972...76,861,165
|
|
G |
Ccnd3 |
cyclin D3 |
multiple interactions |
ISO |
[monoethyl phthalate co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono-isobutyl phthalate co-treated with monoisononylphthalate co-treated with mono-benzyl phthalate] results in decreased expression of CCND3 mRNA |
CTD |
PMID:31884101 |
|
NCBI chr 9:15,404,816...15,410,905
Ensembl chr 9:15,404,822...15,410,943
|
|
G |
Ccne1 |
cyclin E1 |
multiple interactions |
ISO |
[monoethyl phthalate co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono-isobutyl phthalate co-treated with monoisononylphthalate co-treated with mono-benzyl phthalate] results in decreased expression of CCNE1 mRNA |
CTD |
PMID:31884101 |
|
NCBI chr 1:94,485,830...94,495,112
Ensembl chr 1:94,485,832...94,494,980
|
|
G |
Ccr7 |
C-C motif chemokine receptor 7 |
multiple interactions |
ISO |
[bisphenol A co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono-benzyl phthalate co-treated with monobutyl phthalate] results in increased expression of CCR7 mRNA |
CTD |
PMID:30398665 |
|
NCBI chr10:87,057,335...87,067,444
Ensembl chr10:87,057,136...87,067,456
|
|
G |
Cd163 |
CD163 molecule |
multiple interactions |
ISO |
[bisphenol A co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono-benzyl phthalate co-treated with monobutyl phthalate] results in decreased expression of CD163 mRNA |
CTD |
PMID:30398665 |
|
NCBI chr 4:156,752,063...156,785,467
Ensembl chr 4:156,752,082...156,785,467
|
|
G |
Cdk2 |
cyclin dependent kinase 2 |
multiple interactions |
ISO |
[monoethyl phthalate co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono-isobutyl phthalate co-treated with monoisononylphthalate co-treated with mono-benzyl phthalate] results in decreased expression of CDK2 mRNA |
CTD |
PMID:31884101 |
|
NCBI chr 7:3,124,953...3,132,533
Ensembl chr 7:3,124,954...3,132,457
|
|
G |
Cdk4 |
cyclin-dependent kinase 4 |
multiple interactions |
ISO |
[monoethyl phthalate co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono-isobutyl phthalate co-treated with monoisononylphthalate co-treated with mono-benzyl phthalate] results in decreased expression of CDK4 mRNA |
CTD |
PMID:31884101 |
|
NCBI chr 7:70,345,971...70,352,689
Ensembl chr 7:70,349,863...70,352,418
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
multiple interactions |
ISO |
[monoethyl phthalate co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono-isobutyl phthalate co-treated with monoisononylphthalate co-treated with mono-benzyl phthalate] results in increased expression of CDKN1A mRNA |
CTD |
PMID:31884101 |
|
NCBI chr20:6,348,422...6,358,864
Ensembl chr20:6,351,458...6,358,864
|
|
G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
multiple interactions |
ISO |
[monoethyl phthalate co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono-isobutyl phthalate co-treated with monoisononylphthalate co-treated with mono-benzyl phthalate] results in decreased expression of CDKN1B mRNA |
CTD |
PMID:31884101 |
|
NCBI chr 4:168,689,043...168,694,159
Ensembl chr 4:168,689,163...168,693,964
|
|
G |
Cdkn1c |
cyclin-dependent kinase inhibitor 1C |
multiple interactions |
ISO |
[monoethyl phthalate co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono-isobutyl phthalate co-treated with monoisononylphthalate co-treated with mono-benzyl phthalate] results in decreased expression of CDKN1C mRNA |
CTD |
PMID:31884101 |
|
NCBI chr 1:216,661,067...216,663,791
Ensembl chr 1:216,661,080...216,663,721
|
|
G |
Cdkn2a |
cyclin-dependent kinase inhibitor 2A |
multiple interactions |
ISO |
[monoethyl phthalate co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono-isobutyl phthalate co-treated with monoisononylphthalate co-treated with mono-benzyl phthalate] results in increased expression of CDKN2A mRNA |
CTD |
PMID:31884101 |
|
NCBI chr 5:107,823,323...107,832,405
Ensembl chr 5:107,823,330...107,841,175
|
|
G |
Cdkn2b |
cyclin-dependent kinase inhibitor 2B |
multiple interactions |
ISO |
[monoethyl phthalate co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono-isobutyl phthalate co-treated with monoisononylphthalate co-treated with mono-benzyl phthalate] results in increased expression of CDKN2B mRNA |
CTD |
PMID:31884101 |
|
NCBI chr 5:107,834,353...107,857,428
Ensembl chr 5:107,845,951...107,858,104
|
|
G |
Cdkn2c |
cyclin-dependent kinase inhibitor 2C |
multiple interactions |
ISO |
[monoethyl phthalate co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono-isobutyl phthalate co-treated with monoisononylphthalate co-treated with mono-benzyl phthalate] results in decreased expression of CDKN2C mRNA |
CTD |
PMID:31884101 |
|
NCBI chr 5:129,347,731...129,352,886
Ensembl chr 5:129,347,732...129,352,886
|
|
G |
Cdkn2d |
cyclin dependent kinase inhibitor 2D |
multiple interactions |
ISO |
[monoethyl phthalate co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono-isobutyl phthalate co-treated with monoisononylphthalate co-treated with mono-benzyl phthalate] affects the expression of CDKN2D mRNA |
CTD |
PMID:31884101 |
|
|
|
G |
Cga |
glycoprotein hormones, alpha polypeptide |
increases expression affects expression increases secretion |
ISO |
mono-benzyl phthalate results in increased expression of CGA mRNA mono-benzyl phthalate affects the expression of CGA mRNA mono-benzyl phthalate results in increased secretion of CGA protein |
CTD |
PMID:28381288 PMID:29089286 |
|
NCBI chr 5:50,362,491...50,393,368
Ensembl chr 5:50,381,244...50,393,367
|
|
G |
Crp |
C-reactive protein |
increases expression |
ISO |
mono-benzyl phthalate results in increased expression of CRP protein |
CTD |
PMID:21349512 |
|
NCBI chr13:91,080,448...91,081,358
Ensembl chr13:91,054,974...91,093,713
|
|
G |
Cxcl10 |
C-X-C motif chemokine ligand 10 |
multiple interactions |
ISO |
[bisphenol A co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono-benzyl phthalate co-treated with monobutyl phthalate] results in increased expression of CXCL10 mRNA |
CTD |
PMID:30398665 |
|
NCBI chr14:17,210,733...17,212,930
Ensembl chr14:17,210,733...17,212,930
|
|
G |
Cyp11a1 |
cytochrome P450, family 11, subfamily a, polypeptide 1 |
increases expression multiple interactions affects expression |
ISO |
mono-benzyl phthalate results in increased expression of CYP11A1 mRNA [monoethyl phthalate co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono-isobutyl phthalate co-treated with monoisononylphthalate co-treated with mono-benzyl phthalate] results in decreased expression of CYP11A1 mRNA mono-benzyl phthalate affects the expression of CYP11A1 mRNA |
CTD |
PMID:28381288 PMID:29089286 PMID:31884101 |
|
NCBI chr 8:62,798,317...62,809,848
Ensembl chr 8:62,779,875...62,809,893
|
|
G |
Cyp17a1 |
cytochrome P450, family 17, subfamily a, polypeptide 1 |
multiple interactions |
ISO |
[monoethyl phthalate co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono-isobutyl phthalate co-treated with monoisononylphthalate co-treated with mono-benzyl phthalate] results in decreased expression of CYP17A1 mRNA |
CTD |
PMID:31884101 |
|
NCBI chr 1:266,422,127...266,429,947
Ensembl chr 1:266,422,132...266,428,239
|
|
G |
Cyp19a1 |
cytochrome P450, family 19, subfamily a, polypeptide 1 |
affects expression multiple interactions |
ISO |
mono-benzyl phthalate affects the expression of CYP19A1 mRNA [monoethyl phthalate co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono-isobutyl phthalate co-treated with monoisononylphthalate co-treated with mono-benzyl phthalate] results in decreased expression of CYP19A1 mRNA |
CTD |
PMID:28381288 PMID:31884101 |
|
NCBI chr 8:58,744,849...58,772,408
Ensembl chr 8:58,744,849...58,772,408
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
multiple interactions |
ISO |
[monoethyl phthalate co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono-isobutyl phthalate co-treated with monoisononylphthalate co-treated with mono-benzyl phthalate] results in increased expression of CYP1A1 mRNA |
CTD |
PMID:31884101 |
|
NCBI chr 8:62,472,087...62,478,122
Ensembl chr 8:62,472,095...62,478,147
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
multiple interactions |
ISO |
[monoethyl phthalate co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono-isobutyl phthalate co-treated with monoisononylphthalate co-treated with mono-benzyl phthalate] results in decreased expression of CYP1B1 mRNA |
CTD |
PMID:31884101 |
|
NCBI chr 6:2,308,179...2,316,739
Ensembl chr 6:2,307,808...2,316,722
|
|
G |
Cyp2b1 |
cytochrome P450, family 2, subfamily b, polypeptide 1 |
decreases activity |
EXP |
mono-benzyl phthalate results in decreased activity of CYP2B1 protein |
CTD |
PMID:27432241 |
|
NCBI chr 7:99,142,431...99,183,540
Ensembl chr 7:99,142,450...99,181,783
|
|
G |
Cyp3a62 |
cytochrome P450, family 3, subfamily a, polypeptide 62 |
decreases activity |
EXP |
mono-benzyl phthalate results in decreased activity of CYP3A62 protein |
CTD |
PMID:27432241 |
|
NCBI chr12:18,679,809...18,709,397
Ensembl chr12:18,678,594...18,709,397
|
|
G |
Ereg |
epiregulin |
increases expression |
ISO |
mono-benzyl phthalate results in increased expression of EREG mRNA |
CTD |
PMID:29089286 |
|
NCBI chr14:18,577,620...18,591,395
Ensembl chr14:18,576,355...18,591,394
|
|
G |
Esr1 |
estrogen receptor 1 |
multiple interactions |
ISO |
mono-benzyl phthalate promotes the reaction [Estradiol results in increased activity of ESR1 protein] [monoethyl phthalate co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono-isobutyl phthalate co-treated with monoisononylphthalate co-treated with mono-benzyl phthalate] results in decreased expression of ESR1 mRNA |
CTD |
PMID:28571686 PMID:31884101 |
|
NCBI chr 1:41,192,029...41,594,799
Ensembl chr 1:41,192,824...41,594,796
|
|
G |
Esr2 |
estrogen receptor 2 |
multiple interactions |
ISO |
mono-benzyl phthalate promotes the reaction [Estradiol results in increased activity of ESR2 protein] [monoethyl phthalate co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono-isobutyl phthalate co-treated with monoisononylphthalate co-treated with mono-benzyl phthalate] results in decreased expression of ESR2 mRNA |
CTD |
PMID:28571686 PMID:31884101 |
|
NCBI chr 6:99,163,953...99,214,711
Ensembl chr 6:99,164,357...99,214,251
|
|
G |
Flg |
filaggrin |
multiple interactions |
ISO |
[FLG gene polymorphism affects the susceptibility to butylbenzyl phthalate] which affects the abundance of mono-benzyl phthalate |
CTD |
PMID:24380925 |
|
NCBI chr 2:193,565,401...193,574,297
|
|
G |
Fshr |
follicle stimulating hormone receptor |
multiple interactions |
ISO |
[monoethyl phthalate co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono-isobutyl phthalate co-treated with monoisononylphthalate co-treated with mono-benzyl phthalate] results in decreased expression of FSHR mRNA |
CTD |
PMID:31884101 |
|
NCBI chr 6:12,796,383...12,997,817
Ensembl chr 6:12,796,383...12,997,817
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
multiple interactions |
ISO |
[monoethyl phthalate co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono-isobutyl phthalate co-treated with monoisononylphthalate co-treated with mono-benzyl phthalate] results in decreased expression of GPX1 mRNA |
CTD |
PMID:31884101 |
|
NCBI chr 8:117,117,430...117,118,528
Ensembl chr 8:117,117,430...117,118,522
|
|
G |
Gsr |
glutathione-disulfide reductase |
multiple interactions |
ISO |
[monoethyl phthalate co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono-isobutyl phthalate co-treated with monoisononylphthalate co-treated with mono-benzyl phthalate] results in increased expression of GSR mRNA |
CTD |
PMID:31884101 |
|
NCBI chr16:62,197,617...62,239,987
Ensembl chr16:62,197,617...62,241,361
|
|
G |
Hsd17b1 |
hydroxysteroid (17-beta) dehydrogenase 1 |
multiple interactions |
ISO |
[monoethyl phthalate co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono-isobutyl phthalate co-treated with monoisononylphthalate co-treated with mono-benzyl phthalate] results in decreased expression of HSD17B1 mRNA |
CTD |
PMID:31884101 |
|
NCBI chr10:88,987,558...88,989,758
Ensembl chr10:88,987,558...88,989,757
|
|
G |
Hsd3b1 |
hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1 |
multiple interactions |
ISO |
[monoethyl phthalate co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono-isobutyl phthalate co-treated with monoisononylphthalate co-treated with mono-benzyl phthalate] results in decreased expression of HSD3B1 mRNA |
CTD |
PMID:31884101 |
|
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
[bisphenol A co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono-benzyl phthalate co-treated with monobutyl phthalate] results in increased expression of IL6 mRNA |
CTD |
PMID:30398665 |
|
NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
|
|
G |
Lhcgr |
luteinizing hormone/choriogonadotropin receptor |
multiple interactions |
ISO |
[monoethyl phthalate co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono-isobutyl phthalate co-treated with monoisononylphthalate co-treated with mono-benzyl phthalate] results in decreased expression of LHCGR mRNA |
CTD |
PMID:31884101 |
|
NCBI chr 6:12,493,182...12,554,482
Ensembl chr 6:12,493,943...12,554,439
|
|
G |
Mki67 |
marker of proliferation Ki-67 |
multiple interactions |
ISO |
[monoethyl phthalate co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono-isobutyl phthalate co-treated with monoisononylphthalate co-treated with mono-benzyl phthalate] results in decreased expression of MKI67 mRNA |
CTD |
PMID:31884101 |
|
NCBI chr 1:207,993,895...208,020,454
Ensembl chr 1:207,993,895...208,020,454
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions |
ISO |
[bisphenol A co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono-benzyl phthalate co-treated with monobutyl phthalate] results in increased secretion of MMP9 protein |
CTD |
PMID:30398665 |
|
NCBI chr 3:161,413,410...161,421,473
Ensembl chr 3:161,413,298...161,421,520
|
|
G |
Mrc1 |
mannose receptor, C type 1 |
multiple interactions |
ISO |
[bisphenol A co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono-benzyl phthalate co-treated with monobutyl phthalate] results in decreased expression of MRC1 mRNA |
CTD |
PMID:30398665 |
|
NCBI chr17:81,352,700...81,433,743
Ensembl chr17:81,352,700...81,433,743
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
increases activity |
ISO |
mono-benzyl phthalate results in increased activity of NR1I2 protein |
CTD |
PMID:27551952 |
|
NCBI chr11:65,022,100...65,058,546
Ensembl chr11:65,022,100...65,058,545
|
|
G |
Nr1i3 |
nuclear receptor subfamily 1, group I, member 3 |
increases activity multiple interactions |
ISO |
mono-benzyl phthalate results in increased activity of NR1I3 protein alternative form [monoethyl phthalate co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono-isobutyl phthalate co-treated with monoisononylphthalate co-treated with mono-benzyl phthalate] results in increased expression of NR1I3 mRNA |
CTD |
PMID:27551952 PMID:31884101 |
|
NCBI chr13:89,585,072...89,591,278
Ensembl chr13:89,586,283...89,591,277
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
affects binding multiple interactions increases activity |
ISO |
mono-benzyl phthalate binds to PPARA protein [monoethyl phthalate co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono-isobutyl phthalate co-treated with monoisononylphthalate co-treated with mono-benzyl phthalate] results in decreased expression of PPARA mRNA mono-benzyl phthalate results in increased activity of PPARA protein |
CTD |
PMID:23843199 PMID:27551952 PMID:31884101 |
|
NCBI chr 7:126,618,872...126,687,282
Ensembl chr 7:126,619,196...126,681,752
|
|
G |
Ppard |
peroxisome proliferator-activated receptor delta |
affects binding multiple interactions increases activity |
ISO |
mono-benzyl phthalate binds to PPARB protein [monoethyl phthalate co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono-isobutyl phthalate co-treated with monoisononylphthalate co-treated with mono-benzyl phthalate] results in increased expression of PPARD mRNA mono-benzyl phthalate results in increased activity of PPARD protein |
CTD |
PMID:23843199 PMID:27551952 PMID:31884101 |
|
NCBI chr20:7,818,289...7,883,482
Ensembl chr20:7,818,289...7,885,333
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
affects binding multiple interactions increases expression increases activity |
ISO |
mono-benzyl phthalate binds to PPARG protein [monoethyl phthalate co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono-isobutyl phthalate co-treated with monoisononylphthalate co-treated with mono-benzyl phthalate] results in increased expression of PPARG mRNA mono-benzyl phthalate results in increased expression of PPARG protein mono-benzyl phthalate results in increased activity of PPARG protein |
CTD |
PMID:23843199 PMID:27551952 PMID:29089286 PMID:31884101 |
|
NCBI chr 4:147,274,055...147,399,383
Ensembl chr 4:147,274,107...147,399,380
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
affects expression |
ISO |
mono-benzyl phthalate affects the expression of PTGS2 mRNA |
CTD |
PMID:29089286 |
|
NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335
|
|
G |
Shbg |
sex hormone binding globulin |
multiple interactions decreases secretion |
ISO |
[Phthalic Acids results in increased abundance of mono-benzyl phthalate] which results in increased expression of and results in increased secretion of SHBG protein mono-benzyl phthalate results in decreased secretion of SHBG protein |
CTD |
PMID:24945889 PMID:28637469 |
|
NCBI chr10:56,219,861...56,237,354
Ensembl chr10:56,219,858...56,223,245
|
|
G |
Skp2 |
S-phase kinase associated protein 2 |
multiple interactions |
ISO |
[monoethyl phthalate co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono-isobutyl phthalate co-treated with monoisononylphthalate co-treated with mono-benzyl phthalate] results in decreased expression of SKP2 mRNA |
CTD |
PMID:31884101 |
|
NCBI chr 2:58,506,146...58,534,211
Ensembl chr 2:58,506,151...58,534,211
|
|
G |
Star |
steroidogenic acute regulatory protein |
multiple interactions |
ISO |
[monoethyl phthalate co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono-isobutyl phthalate co-treated with monoisononylphthalate co-treated with mono-benzyl phthalate] results in increased expression of STAR mRNA |
CTD |
PMID:31884101 |
|
NCBI chr16:71,036,204...71,040,847
Ensembl chr16:71,036,204...71,040,847
|
|
|
G |
Alb |
albumin |
multiple interactions |
ISO |
ALB protein binds to and affects the transport of salicin |
CTD |
PMID:8831264 |
|
NCBI chr14:19,176,275...19,191,793
Ensembl chr14:19,176,277...19,191,863
|
|
G |
Tas2r118 |
taste receptor, type 2, member 118 |
multiple interactions increases activity |
ISO |
4-((diethylamino)sulfonyl)benzoic acid inhibits the reaction [salicin results in increased activity of TAS2R16 protein]; Probenecid inhibits the reaction [salicin results in increased activity of TAS2R16 protein] |
CTD |
PMID:21629661 |
|
NCBI chr 4:51,002,218...51,003,117
Ensembl chr 4:51,002,218...51,003,117
|
|
|
G |
Alb |
albumin |
multiple interactions |
ISO |
ALB protein binds to and affects the transport of salicyl alcohol |
CTD |
PMID:8831264 |
|
NCBI chr14:19,176,275...19,191,793
Ensembl chr14:19,176,277...19,191,863
|
|
G |
Bche |
butyrylcholinesterase |
multiple interactions |
ISO |
[2-(2-cresyl)-4H-1-3-2-benzodioxaphosphorin-2-oxide binds to and results in decreased activity of BCHE protein] which results in increased abundance of salicyl alcohol |
CTD |
PMID:22898212 |
|
NCBI chr 2:171,104,476...171,196,186
Ensembl chr 2:171,100,140...171,196,395
|
|
G |
Sod2 |
superoxide dismutase 2 |
multiple interactions |
EXP |
salicyl alcohol inhibits the reaction [2,2'-azobis(2-amidinopropane) results in decreased activity of SOD2 protein] |
CTD |
PMID:19665455 |
|
NCBI chr 1:47,914,757...47,921,587
Ensembl chr 1:47,914,759...47,921,587
|
|